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Abstract
Converging evidence from neuroimaging, pharmacological and molecular studies suggests that 
serotonin 2A (5-HT2A) and 1A (5-HT1A) subreceptors are involved in the pathophysiology of 
 negative emotional processing biases in affective disorders. This view is supported by the finding 
that 5-HT1A and 5-HT2A receptor densities are altered in prefrontal and limbic regions in patients 
with depression and anxiety disorders. Furthermore, 5-HT1A receptor agonists are  effective at 
enhancing the antidepressant effect of selective serotonin reuptake inhibitors, and preferential 
5-HT2A receptor agonists exhibit anxiolytic and antidepressant effects in animal models of affec-
tive disorders. The hallucinogen psilocybin, which activates 5-H2A and 1A receptors, was recently 
found to acutely enhances mood in healthy subjects and to reduce depression and anxiety symp-
toms in terminal cancer patients. However, the effect of psilocybin on the emotional processing 
biases across different psychological domains, and the specific contribution of 5-HT2A receptor 
activation, remain unknown. 
In addition, the 5-HT2A and 1A receptors are highly expressed in visual pathways and aberrant 
5-HT2A receptor expression has been associated with the formation of visual hallucinations in 
Parkinson’s disease and schizophrenia. Furthermore, activation of 5-HT2A receptors is thought 
to be predominantly responsible for psilocybin-induced visual hallucinations. However, the neu-
rophysiological mechanisms that mediate between 5-HT2A receptor activation and the forma-
tion of visual hallucinations in psilocybin-induced and pathological states remain undefined. 
To clarify these issues further, we assessed in the first study (Chapter 2) the effects of psilocybin 
(215 µg/kg vs. placebo) on emotional processing bias in face recognition, goal-directed behav-
iour and mood states in 17 healthy subjects. To disentangle the specific contribution of 5-HT2A 
receptors, subjects were pretreated with the preferential 5-HT2A receptor antagonist ketanserin 
(50 mg vs. placebo). Psilocybin biased emotional processing towards positive information across 
different psychological domains. Specifically, psilocybin enhanced positive mood states and 
 disrupted the recognition of negative facial expressions. Furthermore, psilocybin increased 
 goal-directed behaviour towards positive cues, facilitated positive but inhibited negative sequen-
tial emotional effects, and more strongly decreased the P300 potential for negative and neutral 
stimuli than for positive stimuli. Ketanserin selectively blocked the psilocybin-induced mood 
 enhancement and the disruption in the recognition of negative facial expression, indicating that 
5-HT2A receptor activation mediates these psilocybin-induced effects.
In the second study (Chapter 3), we assessed the effects of two doses of psilocybin (125 and 
250 µg/kg vs. placebo) on the spatiotemporal dynamics of visual modal object completion in 
17 healthy subjects using visual-evoked potential recordings in conjunction with topographic 
mapping and sLORETA source analysis. These physiological effects were related to the subjective 
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intensity of psilocybin-induced visual hallucinations, as quantified by psychometric measure-
ment. Psilocybin elicited a dose-dependent increase in the medial P1 potential, reflecting ampli-
fied activity in early visual areas. By contrast, there was a strong dose-dependent decrease in the 
N170 potential, which was most apparent during the processing of incomplete object figures 
and therefore indicates aberrant modal object completion. The overall reduction in activity of 
the right extrastriate and posterior parietal areas during the period of the N170 potential was 
further positively correlated with the intensity of visual hallucinations. 
It is possible that 5-HT2A receptor activation mediates the psilocybin-induced effects on the 
visual evoked potential during modal object completion and additionally increases the excit-
ability of the visual cortex which, in turn, underlies the psilocybin-induced visual hallucinations. 
This hypothesis was tested in the third study (Chapter 4). Specifically, we assessed the effect of 
psilocybin (215 µg/kg vs. placebo) on the alpha oscillations that regulate cortical excitability 
and on the early visual-evoked potentials (P1 and N170) in 15 healthy subjects. To delineate the 
specific contribution of 5-HT2A receptors, subjects were pretreated with ketanserin (50 mg vs. 
placebo). Psilocybin selectively increased the medial P1 potential, confirming the results of study 
two, and ketanserin selectively decreased the P1 potential over the same electrode sites. The 
subsequent N170 potential was decreased by psilocybin and associated with perceptual altera-
tions. Both the N170 potential and the perceptual alterations were blocked by ketanserin, which 
 suggests that the reduction of the N170 potential may underlie 5-HT2A receptor-mediated 
visual hallucinations. Finally, psilocybin strongly decreased the prestimulus alpha power and 
blocked the stimulus-induced alpha desynchronization, and both of these effects were reversed 
by ketanserin. This suggests that 5-HT2A receptor activation induces a processing mode in which 
stimulus-driven excitation is overwhelmed by spontaneously patterned neuronal excitation. 
Taken together, these findings indicate that psilocybin markedly modulates conscious, behav-
ioural and neurophysiological indices of visual and emotional processing through 5-HT2A recep-
tor activation. The identified effect of 5-HT2A receptor activation on the emotional processing 
bias provides a potential mechanism for the pathophysiology of dysfunctional emotional biases 
in depression, thereby providing a framework to test the putative antidepressant effects of 
 psilocybin and related substances in affective disorders. Furthermore, the present studies 
 revealed several 5-HT2A dependent neurophysiological mechanisms underlying aberrant visual 
processing. A reduction in the N170 potential was identified as a key process in 5-HT2A receptor-
mediated visual hallucinations and aberrant object completion that may not be implicated only 
in psilocybin-induced states, but also in the pathophysiology of hallucinations in schizophrenia 
and Parkinson’s disease.
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Zusammenfassung
Konvergierende Befunde von bildgebenden, pharmakologischen und molekularen Studien weisen 
darauf hin, dass die serotonergen 2A (5-HT2A) und 1A (5-HT1A) Subrezeptoren eine zentrale 
Rolle in der Pathophysiologie von negativen emotionalen Verarbeitungstendenzen in affektiven 
Erkrankungen spielen. Diese Sichtweise basiert einerseits auf dem Befund, dass depressive 
 Patienten sowie Angstpatienten eine veränderte Dichte von 5-HT2A und 1A Rezeptoren inner-
halb präfrontaler und limischer Regionen aufweisen. Des Weiteren verstärkt die kombinierte 
Gabe von 5-HT1A Rezeptor Agonisten die antidepressive Wirkung von SSRIs und präferentielle 
5-HT2A Rezeptor Agonisten zeigen antidepressive und angstlösende Wirkungen in verschiede-
nen Tiermodellen von Emotionserkrankungen. Das Halluzinogen Psilocybin stimuliert 5-HT2A 
und 1A  Rezeptoren und führte in kürzlich veröffentlichten Studien zu einer akuten Stimmungs-
aufhellung bei gesunden Probanden und zu einer Reduktion von Depressions- und Angst-
symptome bei Krebspatienten. Die Effekte von Psilocybin auf die emotionalen Verarbeitungsten-
denzen in  verschiedenen psychologischen Domänen, sowie der spezifische Beitrag der 5-HT2A 
Rezeptor aktivierung, bleiben jedoch unbekannt.
Die 5-HT2A und 1A Rezeptoren werden des Weiteren mit einer hohen Dichte in visuellen kor-
tikalen Verarbeitungsstrecken exprimiert, und Veränderungen der Expression wurden kürzlich 
mit der Entstehung von visuellen Halluzinationen bei Parkinson und Schizophrenie Patienten in 
Verbindung gebracht. Ferner unterliegt die Aktivierung von 5-HT2A Rezeptoren wahrscheinlich 
den Psilocybin-induzierten visuellen Halluzinationen. Dennoch sind die neuophysiologischen 
Mechanismen, welche zwischen der Aktivierung von 5-HT2A Rezeptoren und der Bildung von 
visuellen Halluzinationen vermitteln, weitgehend unbekannt.
Um diese offenen Fragen zu klären, wurden in der ersten Studie (Kapitel 2) die Effekte von Psilo-
cybin (215 µg/kg vs. Placebo) auf die Stimmung und die emotionalen Verarbeitungstendenzen 
in der Gesichtswahrnehmung sowie dem zielgerichteten Verhalten bei 17 gesunden Probanden 
untersucht. Um den spezifischen Beitrag des 5-HT2A Rezeptors zu isolieren, wurde den Pro-
banden zusätzlich der präferenzielle 5-HT2A Rezeptor Antagonist Ketanserin (50 mg vs. Placebo) 
verabreicht. Die Befunde ergaben, dass Psilocybin über verschiedene psychologische Domänen 
konsistent eine präferenzielle Verarbeitung von positiven im Vergleich zu negativen Emotionen 
induzierte. D.h. Psilocybin löste positive Gefühlszustände aus und beeinträchtigte die Erkennung 
von negativen Gesichtsausdrücken. Psilocybin führte des Weiteren zu einer Verschiebung des 
zielgerichteten Verhaltens hin zu positiven Emotionen, förderte die positiven nicht aber die 
 negativen sequentiellen emotionalen Effekte, und reduzierte das P300 Potential stärker auf 
 negative und neutrale Reize im Vergleich zu positiven Reizen. Ein zentraler Beitrag des 5-HT2A 
Rezeptors in der Vermittlung der Psilocybin-induzierten positiven Gefühlzuständen sowie der 
Zusammenfassung 9
reduzierten Erkennung von negativen Gesichtsausdrücken ist dadurch ersichtlich, dass Ketan-
serin diese Psilocybin-induzierte Effekte blockierte. 
In der zweiten Studie (Kapitel 3) wurden die Effekte von zwei Dosen Psilocybin (125 und 
250 µg/kg vs. Placebo) auf die räumlich-zeitliche Dynamik der visuellen modalen Objektver-
vollständigung bei 17 gesunden Probanden mittels der Aufzeichnung von visuell evozierten 
 Potentialen in Verbindung mit topographischer Analyse und sLORETA Quellenschätzung unter-
sucht. Diese physiologischen Effekte wurden anschliessend in Bezug zur psychometrisch quanti-
fizierter Intensität von visuellen Halluzinationen gesetzt. Psilocybin erhöhte dosisabhängig das 
mediale P1 Potential, was eine verstärkte Aktivierung in frühen visuellen Arealen wiederspiegel-
te. Im Gegensatz dazu wurde das N170 Potential dosisabhängig reduziert, was für unvollständige 
 Figuren besonders ausgeprägt war und somit auf eine veränderte Objektvervollständigung hin-
deutet. Die generelle Aktivierungsabnahme in rechts lateralisierten extrastriären und posterior 
parietalen Arealen korrelierte positiv mit der Intensität visueller Halluzinationen. 
Möglicherweise ist die Aktivierung des 5-HT2A Rezeptors für die Effekte von Psilocybin auf die 
visuell-evozierten Potentiale während der modalen Objektvervollständigung verantwortlich und 
führt außerdem zu einer erhöhten Erregbarkeit des visuellen Kortex, was in der Bildung von 
 Psilocybin-induzierten visuellen Halluzinationen unterliegen könnte. Um diese Hypothesen zu 
prüfen wurden in der dritten Studie (Kapitel 4) die Effekte von Psilocybin (215 µg/kg vs. Placebo) 
auf die alpha Oszillationen, welche die Erregbarkeit regulieren, sowie auf die früher visuell evo-
zierten Potentiale (P1 und N170) bei 15 gesunden Probanden untersucht. Um den spezifischen 
Beitrag des 5-HT2A Rezeptors zu isolieren, wurde den Probanden zudem der präferentielle 
5-HT2A Rezeptor Antagonist Ketanserin verabreicht (50 mg vs. Placebo). Die Befunde ergaben, 
dass Psilocybin wie bereits in Studie 2 selektiv die mediale P1 erhöht, Ketanserin das P1 Potential 
jedoch über den gleichen medialen Elektroden reduziert. Ferner wurde das darauffolgende N170 
Potential durch Psilocybin reduziert, was mit dem Erscheinen von perzeptuellen Störungen ein-
herging. Da sowohl die N170 Reduktion als auch die perzeptuellen Störungen durch Ketanserin-
vorbehandlung aufgehoben wurden, unterliegt diesen Veränderungen wahrscheinlich die Akti-
vierung des 5-HT2A Rezeptors. Schliesslich stellten wir fest, dass Psilocybin die Power der alpha 
Oszillationen vor dem Erscheinen visueller Reize reduzierte, hingegen die Stimulus induzierte 
Alpha Desynchronization blockierte – zwei Effekte, die wiederum durch Ketanserinvorbehand-
lung aufgehoben wurden. Dies legt nahe, dass die Aktivierung von 5-HT2A Rezeptoren einen 
 visuellen Verarbeitungsmodus induziert, welcher dadurch gekennzeichnet ist, dass die Stimulus-
induzierte Erregung von spontan strukturierter neuronaler Erregung überwältigt wird.
Zusammenfassend deuten diese Befunde darauf hin, dass Psilocybin die bewussten, die verhaltens-
bezogenen und die neurophysiologischen Prozesse der emotionalen und visuellen Verarbeitung 
hauptsächlich durch die Aktivierung von 5-HT2A Rezeptoren moduliert. Der identifizierte Effekt 
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der 5-HT2A Rezeptoraktivierung auf die emotionale Verarbeitungstendenzen stellt einerseits 
 einen möglichen Mechanisms dar, welcher für die Pathophysiologie von dysfunktionalen emo-
tionalen Verarbeitungstendenzen in der Depression wichtig sein könnte, und legt andererseits 
ein Rahmenprogramm nahe, um den mutmasslichen antidepressiven Effekt von Psilocybin und 
verwandten Substanzen in affektiven Störungen weiter zu elaborieren. Des Weiteren deckten 
die experimentellen Studien verschiedene 5-HT2A Rezeptor-abhängige neurophysiologische 
 Mechanismen der veränderten visuellen Verarbeitung auf. Insbesondere wurde die Reduktion 
des N170 Potentials durch die 5-HT2A Rezeptoraktivierung als ein Schlüsselprozess in der 
 Vermittlung von visuellen Halluzinationen und veränderter modalen Objektvervollständigung 
identifiziert, welche nicht nur in den Psilocybin-induzierten Zuständen, sondern auch in der 
 Pathophysiologie der Schizophrenie und der Parkinson-Erkrankung eine zentrale Rolle spielen 
könnte.

General introduction
1
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1.1  Significance of 5-HT2A and 1A receptors in emotional  
and visual processing
Increasing evidence point to a critical role for the 5-HT2A and 1A receptors in emotional and  visual 
processing and suggest that these receptors are implicated in the pathogenesis of  various psychi-
atric disorders, including schizophrenia, Parkinson’s disease, mood and anxiety disorders. 
The importance of the 5-HT2A and 1A receptors in emotional processing is indicated by the 
high expression levels of these receptors in an extended prefrontal-limbic network (Weisstaub et 
al., 2006; Albert and François, 2010; Richardson-Jones et al., 2010) that underlies emotional 
functions, including emotional control and recognition (Pessoa and Adolphs, 2010; Disner et al., 
2011). Furthermore, alterations in 5-HT2A and 5-HT1A receptor densities were found in depres-
sive (Yatham et al., 1999; Albert and François, 2010), bipolar (Sullivan et al., 2009; Yatham et al., 
2010), and anxiety disorders (Perani et al., 2008; Akimova et al., 2009), which suggests that these 
receptors are also involved in the pathophysiology of mood and anxiety disorders. For instance, 
in patients with major depression, the prefrontal 5-HT2A receptor density is increased (Meyer et 
al., 1999; Meyer et al., 2001; Bhagwagar et al., 2006; Shelton et al., 2009), which is associated 
with pessimistic thinking (Meyer et al., 2003; Bhagwagar et al., 2006) and suicidal behaviour 
(Pandey et al., 2002; Oquendo et al., 2006; Shelton et al., 2009). Accordingly, the 5-HT2A and 
5-HT1A receptors could be a key target in the treatment of emotional dysfunctions. This view 
is supported by the finding that chronic treatment with selective serotonin reuptake inhibitors 
(SSRIs) downregulates 5-HT2A receptors in the prefrontal cortex (PFC) in temporal association 
with the onset of clinical efficacy (Sibille et al., 1997; Gómez-Gil et al., 2004; Yamauchi et al., 2006). 
In addition, 5-HT1A receptors have been implicated in the antidepressive action of SSRIs by the 
findings that 5-HT1A-null mice are unresponsive to SSRI treatment (Santarelli et al., 2003) and that 
a selective reduction of 5-HT1A autoreceptor expression in the nucleus raphe permits a robust 
response to SSRI treatment in mice that do not otherwise respond (Richardson-Jones et al., 2010).
In contrast to the increasingly recognised significance of the 5-HT2A and 1A receptors in emo-
tional processes, their roles in visual processing have only recently been acknowledged. Specifi-
cally, the 5-HT2A (Watakabe et al., 2009; Moreau et al., 2010) and 1A (Dyck and Cynader, 1993; 
Gerstl et al., 2008; Watakabe et al., 2009) receptors are highly expressed in the visual cortex, 
and alterations in their cortical density in Parkinson’s disease (Ballanger et al., 2010; Huot et al., 
2010) and schizophrenia (González-Maeso et al., 2008) are associated with the appearance 
of visual hallucinations. Moreover, the activation of the 5-HT2A receptor by indolamine hallu-
cinogens such as psilocybin induces marked subjective visual distortion and hallucinations 
 (Vollenweider et al., 1998), whereas the unselective 5-HT2A antagonist mianserin (Ikeguchi and 
Kuroda, 1995) and the 5-HT2A receptor inverse agonist pimavanserin (Meltzer et al., 2010) 
 reduced the appearance of visual hallucinations in Parkinson’s disease. 
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1.2  Using the indolamine psilocybin to elucidate  
the role of serotonergic subreceptors in emotional  
and visual  processing
These recently accumulated evidence from molecular, pharmacological and neuroimaging stud-
ies converge on the view that the 5-HT2A and 1A receptors play critical roles in emotional and 
visual processing. Alterations in 5-HT2A and 1A receptors expressions are further implicated in 
the pathogenesis of emotional and visual dysfunctions in various psychiatric disorders, and 
therefore could be key targets in the treatment of visual and emotional dysfunction. However, 
human studies on the roles of the 5-HT1A, and in particular, the 5-HT2A receptors were mostly 
based on post-mortem samples or on PET using radioactive 5-HT2A ligands, such as altanserin, 
to reveal correlations between receptor density and self-reported emotional and visual states 
and traits. Thus, the effects of the activation of the 5-HT1A and especially the 5-HT2A receptors 
on emotional and visual processing functions in human subjects remain largely unknown. Fur-
thermore, the neurophysiological mechanisms that mediated between 5-HT2A receptor activa-
tion on the one hand and emotional dysfunctions and the formation of visual hallucinations on 
the other hand were only addressed in a few animals studies, and therefore remain to be eluci-
dated in further studies. 
 
To elucidate these issues further, in the three experimental studies of this thesis (Chapters 2–4), 
the indolamine hallucinogen psilocybin, whose bioactive metabolite psilocin activates the 
5-HT2A and 1A receptors (Blair et al., 2000; Nichols, 2004) and induce strong subjective visual 
and emotional alterations, was administered to healthy human subjects. The effects on emo-
tional and visual processing and the underlying neurophysiological mechanisms were assessed 
by means of various self-report, behavioural and neurophysiological measurements. Further-
more, in two studies, the specific contribution of the 5-HT2A receptor stimulation to the psilocy-
bin-induced effects was determined by pretreating subjects with the preferential 5-HT2A recep-
tor antagonist ketanserin one hour before psilocybin administration. This pharmacological 
manipulation schema provides the unique prospect of experimentally manipulating the activity 
relative selectively at the 5-HT2A receptor and measuring its effects on psychological and neuro-
physiological processes in human subjects. 
As I will briefly show in the next section, investigations into the effects of indolamine hallucino-
gens not only can contribute to unravelling the serotonergic mechanisms of psychological pro-
cesses (Chapter 1.3.1) but also have a long history of being utilized in psychiatric research, either 
as a research tool to elucidate the psychogenesis of psychiatric disorders or as a therapeutic 
agent (Chapter 1.3.2). I will then show that this conceptual framework of the use of hallucino-
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gens in psychiatric research can be applied to the investigation of emotional (Chapter 1.3.3) and 
visual processes (Chapter 1.3.4) and thereby may lead to unique insides into the pathophysiolo-
gy and treatmet of psychiatric disorders, including mood disorders, schizophrenia and Parkin-
son’s disease. I will infer several preliminary hypotheses based on the sparse knowledge of the 
effects of emotional and visual processing in animals and humans, whereas in Chapter (1.4 and 
1.5), the hypothesis will be specified and the methodological approaches will be delineated.
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1.3 Concepts and evidence in indolamine hallucinogen research
1.3.1  The contribution of indolamine hallucinogens to the understanding  
of the serotonergic system
In the middle of the 20th century the discovery of the similarities in chemical structure between 
indolamines and serotonin suggested that the serotonergic system might be responsible for 
the strong psychological effects of indolamine hallucinogens and further prompted the use of 
indolamine as a research tool to unravel the serotonergic mechanisms underlying psycho-
logical processes (Gaddum, 1953; Woolley and Shaw, 1954). Meanwhile, numerous studies have 
revealed that indolamine hallucinogens are agonists of various serotonin receptors, including 
the 5-HT2A, 5-HT1A, 5-HT2C, and 5-HT7 receptors (Nichols, 2004; Ray, 2010). However, the sub-
jective effects of these hallucinogens are predominantly mediated by agonistic action at the 
5-HT2A receptor (Vollenweider et al., 1998; Carter et al., 2005; Quednow et al., 2011), whereas 
the activation of both the 5-HT1A and 2A receptors appears to contribute to specific behavioural 
effects (Halberstadt and Geyer, 2011; Halberstadt et al., 2011). The activation of cortical 5-HT2A 
receptors by indolamine hallucinogens or serotonin induces an increase in glutamatergic recur-
rent network activity (Béïque et al., 2007; Moreau et al., 2010) associated with a robust increase 
in excitatory postsynaptic currents (EPSCs) predominantly within the layer 5 pyramidal neurons 
(Aghajanian and Marek, 1997, 1999; Béïque et al., 2007; González-Maeso et al., 2007; González-
Maeso et al., 2008) that is thought to be critical in producing the consciousness-altering effects 
of the hallucinogen (Béïque et al., 2007; Aghajanian, 2009). 
In addition to these local cortical effects of 5-HT2A receptor activation, hallucinogen research 
studies contributed to delineating the systemic effects of 5-HT2A receptor stimulation within a 
network comprising the prefrontal cortex, the nucleus raphe and the ventral tegmental area 
(Celada et al., 2001; Puig et al., 2003; Béïque et al., 2007; Vázquez-Borsetti et al., 2009). For 
 instance, activation of 5-HT2A receptors in the mPFC increases the firing rate of serotonergic 
neurons in the dorsal raphe and of dopaminergic neurons in the ventral tegmental areal (VTA), 
resulting in an increased release of 5-HT in the mPFC (Celada et al., 2001; Puig et al., 2003; 
Vázquez-Borsetti et al., 2011) and of dopamine in the mesocortical areas (Vázquez-Borsetti et al., 
2009; Vázquez-Borsetti et al., 2011).
Although these hallucinogen research studies made a strong contribution to the understand-
ing of cellular and systemic serotonergic mechanisms, in particular of prefrontal cortex process-
ing functions, only a small number of studies have used indolamine hallucinogens to delineate 
the serotonergic bases of emotional and visual function. However, from a psychiatric research 
view, these studies may provide unique insights into the psychopathology and treatment of 
 psychiatric disorders. 
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1.3.2  The contribution of indolamine hallucinogens to the understanding  
of the psychophysiology and treatment of psychiatric disorders
The idea to use hallucinogens in psychiatric research derived in the early 1950s from the obser-
vation that indolamine profoundly alter conscious state, characterized by visual illusions and 
hallucinations, heightened mood and euphoria, altered sense of time, and loss of ego boundar-
ies (Studerus et al., 2011). Researchers with different theoretical and experimental background 
have emphasized different aspects of this psilocybin-induced altered state, which resulted in di-
verse approaches to use hallucinogen in psychiatric research (Vollenweider and Kometer, 2010). 
Several researchers emphasised that indolamine hallucinogens can enhance self-awareness 
and can increase the recall of repressed memories (Sandison, 1954; Schmiege, 1963). This unique 
property prompted the use of hallucinogens as an adjunct to facilitate the psychodynamic pro-
cess during psychotherapy (Vollenweider and Kometer, 2010). Accordingly, the therapeutic use 
of indolamines was tested in the 1950s and 1960s in various psychiatric disorders, and numerous 
studies provided particularly promising results in mood and anxiety disorders (Sandison, 1954). 
This history converge with recent findings that 5-HT2A and 1A receptor are implicated in the 
pathophysiology and treatment of mood disorders (Chapter 1.1.) and that indolamines alters the 
functioning of the 5-HT2A and 1A receptor (Chapter 1.3.3). Together these findings indicate that 
an understanding of the emotional effects of psilocybin provides insights into the mechanisms 
underlying mood disorders and the putative antidepressant effect of psilocybin. 
Other researchers from the early 1950s emphasised that indolamines induce perceptual 
 distortions, thought disorder and depersonalisation and derealisation experiences (Hoch et al., 
1952; Leuner, 1962). Because these symptoms similarly occur in psychotic disorders, this 
 perspective has prompted the use of serotonergic hallucinogens as research tools to mimic 
 psychotic states and investigate them under controlled experimental conditions (Geyer and 
 Vollenweider, 2008), a research approach that is known as model psychosis. Meanwhile, this 
 approach have been corroborated by studies showing that 5-HT2A receptor densities in the PFC 
is altered in drug-naive schizophrenic patients (Hurlemann et al., 2008; González-Maeso et al., 
2008) and that antagonism at 5-HT2A receptor is implicated in the effects of atypical antipsy-
chotics such as clozapine, risperidone or olanzapine (Lieberman et al., 1998; Meltzer, 1999) 
(Olajossy-Hilkesberger et al., 2011). However, it must be clearly emphasized that no transient 
state produced by any drug can mimic the entire spectrum of symptoms and dysfunctions of 
a complex group of disorders such as schizophrenia spectrum disorders. In this respect it has 
been shown that psilocybin mimics in particular positive symptoms of psychosis, including visual 
 hallucinations (Gouzoulis-Mayfrank et al., 1998; Geyer and Vollenweider, 2008), which is in line 
with the finding that 5-HT2A receptor density is associated with the formation of visual halluci-
nations in schizophrenia (González-Maeso et al., 2008). Interestingly, increase density of 5-HT2A 
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receptor in visual pathways was recently found in Parkinson’s patients with hallucinations 
 (Ballanger et al., 2010; Huot et al., 2010), which indicates that investigations into the visual 
 effects of psilocybin might not only provide insights into the serotonergic mechanism underlying 
the formation of visual hallucinations in schizophrenia, but also in Parkinson’s disease. 
1.3.3 The effects of indolamine hallucinogens on emotional processing
The mood-enhancing effects of indolamines were early on recognised in unsystematic phenome-
nological studies (DeShon et al., 1952), and the promising therapeutic effect of indolamine 
 hallucinogens in anxiety and depression (Leuner, 1962; Pahnke et al., 1969) suggests that indol-
amines also induce sustainable changes in emotional processing. Although these studies from the 
1950s and 1960s had serious methodological flaws by contemporary standards and remained 
mostly unreplicated after 1970 because of political restrictions, converging lines of recent evi-
dence from animal and human studies support the putative therapeutic potential of indolamines 
in mood and anxiety disorders (Vollenweider and Kometer, 2010). This view is indicated by the 
finding that indolamine hallucinogens induce several neuroplastic adaptations in an extended 
prefrontal-limbic network that are similarly induced by SSRI treatment in depressive subjects and 
are associated with the therapeutic efficacy of SSRIs (Vollenweider and Kometer, 2010). For in-
stance, the indolamine hallucinogen LSD downregulates cortical 5-HT2A but not 5-HT1A receptor 
expression, most prominently in the PFC (Buckholtz et al., 1990; Gresch et al., 2005). This indol-
amine-induced 5-HT2A receptor downregulation might be associated with an anti depressive ef-
fect, as 5-HT2A receptor density was found to be increased in the PFC in patients with depression 
(Meyer et al., 1999; Meyer et al., 2001; Bhagwagar et al., 2006; Shelton et al., 2009) and was 
found to be reduced after chronic treatment with SSRIs at the onset of clinical  efficacy (Sibille et 
al., 1997; Gómez-Gil et al., 2004; Yamauchi et al., 2006). Support for an anti depressive and anxio-
lytic effect of the indolamine hallucinogen DOI was revealed in various  animal models, including 
the elevated plus maze (Nic Dhonnchadha et al., 2003; Massé et al., 2007; Nunes-de-Souza et al., 
2008; Gomes and Nunes-De-Souza, 2009), the elevated T maze (da Silva et al., 2011), the  four-plate 
test (Massé et al., 2007) and tonic immobility (Donatti and Leite-Panissi, 2009). Furthermore, ani-
mal studies revealed that 5-HT2A receptor stimulation has an inhibitory effect on subcortical 
structures, such as the amygdala (Donatti and Leite-Panissi, 2009; Jiang et al., 2009; Hale et al., 
2010; Bombardi, 2011), and the periaqueductal grey (PAG) (Castilho et al., 2002; Millan et al., 
2002; Gomes and Nunes-De-Souza, 2009), which might be beneficial for the treatment of mood 
and anxiety disorders. Most recently, the antidepressive and anxiolytic potential is supported by 
the first recent placebo-controlled pilot study in human terminal cancer patients, which demon-
strated that a single dose of psilocybin led to a gradual reduction in depressive symptoms and trait 
anxiety over a period of six months (Grob et al., 2011). 
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Taken together, these findings on the emotional effects of indolamines are not only in line 
with a key role of 5-HT2A and 1A receptors in emotional processing (Chapter 1.1) but also indi-
cate that indolamines can be used to further the understanding of the serotonergic mechanisms 
 underlying affective disorders and can possibly be even used as agents in the treatment of affec-
tive disorders.
To approach these issues further, we assessed the effects of psilocybin and ketanserin on var-
ious emotional processing biases, which are defined as the preferential processing of positive or 
negative information (Disner et al., 2011; Elliott et al., 2011). Assessing emotional processing 
biases might, on the one hand, be particularly informative because emotional processing biases 
have been strongly implicated in the pathophysiology of affective disorders (Disner et al., 2011). 
In depressed subjects emotional processing is often biased towards negative versus positive 
 information across psychological domains, such as perception, attention, memory and decision-
making (Mathews and MacLeod, 2005; Disner et al., 2011; Roiser et al., 2012). For instance, 
 depressed subjects need more intensely happy facial expressions to correctly label happiness 
(Joormann and Gotlib, 2006) and are slower in responding to positive but not to negative words 
in emotional go/nogo tasks (Murphy et al., 1999; Erickson et al., 2005). On the other hand, a 
crucial role for serotonin (5-HT) in the regulation of emotional biases is evidenced by genetic and 
 pharmacological studies, whereas the differential contributions of 5-HT subreceptors across 
 psychological emotional domains in humans are less well-understood (Elliott et al., 2011; Sharp 
and Cowen, 2011). Therefore, investigations into the effect of psilocybin and ketanserin on emo-
tional processing biases across psychological domains can help to clarify the role of serotonin in 
emotional processing biases. 
1.3.4 The effects of indolamine hallucinogens on visual processing
Surprisingly, the effects of indolamine hallucinogens and 5-HT2A stimulation on visual process-
ing remain largely unknown, although the term “hallucinogen” suggests that understanding vi-
sual hallucinations would be a central research focus. Only sparse knowledge derives from early 
 phenomenological studies indicating that low doses of indolamines induce a subjective increase 
in the brightness of surrounding objects and colours, whereas at medium doses, objects addi-
tionally appear to drift and pulsate (Siegel and Jarvik, 1975). In addition to these perceptual 
 illusions, elementary visual hallucinations of light flashes and simple geometrical  patterns occur. 
Specifically, low-level features of the visual environment are grouped into elementary geo-
metrical patterns, which can be classified into four categories called form constants: (I) tunnels 
and funnels; (II) spirals; (III) latencies, including honeycombs and triangles; and (IV) cobwebs 
(Klüver, 1966). Perceptions of animals, humans or scenes, however, are mostly restricted to the 
closed-eyes condition (Siegel and Jarvik, 1975), indicating that serotonergic hallucinogens more 
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typically induce elementary rather than complex hallucinations. More recently, computational 
models suggested that these elementary visual hallucinations can be caused by an increase in 
the excitability of the visual neuronal network that leads to a destabilisation of spontaneous 
 visual network activity (Ermentrout and Cowan, 1979; Bressloff et al., 2002; Gutkin et al., 2003; 
Butler et al., 2012). The activation of 5-HT2A receptors by the indolamine hallucinogen DOI was 
found to increase the excitability of the visual cortex in rats (Moreau et al., 2010), which support 
the notion that indolamine induce elementary hallucinations by increasing excitability.
The first recent human studies revealed that the psilocybin-induced self-reported perceptual 
alterations, ranging from illusions to elementary and complex hallucinations, can be antagonized 
by ketanserin, which indicates that 5-HT2A receptor activation mediates these visual phenom-
ena (Vollenweider et al., 1998; Carter et al., 2004; Quednow et al., 2011). Furthermore, a human 
neuroimaging study using PET found that psilocybin increased activity in the occipital cortex 
most prominently in lateral rather than medial areas during resting state (Vollenweider et al., 
1997). Psilocybin also disrupted in behavioural task global motion detection, which is thought 
to be mediated by the extrastriate area MT, but not local motion detection, which is resolved in 
V1 (Carter et al., 2004). Together, these findings suggest that psilocybin might exert a stronger 
influence on extrastriatal, rather than striatal functions. 
Taken together, the preliminary findings from indolamine research studies indicate that 
5-HT2A receptor activation by psilocybin might, on the one hand, promote the formation of el-
ementary visual hallucinations by increasing the excitability of the visual cortex and, on the oth-
er hand, disrupt extrastriate processing. To elucidate these issues further, we tested whether 
psilocybin modulates alpha oscillations, which have been identified as the most crucial mecha-
nism in the regulation of excitability in human subjects (Thut et al., 2006; Romei et al., 2008a; 
Jensen and Mazaheri, 2010; Klimesch, 2011; Mathewson et al., 2011), and thereby promotes vi-
sual hallucinations. Furthermore, we assessed the effect of psilocybin on modal object comple-
tion because this fundamental visual process relies heavily on extrastriate visual areas (Hirsch et 
al., 1995; Ffytche and Zeki, 1996; Mendola et al., 1999; Seghier and Vuilleumier, 2006; Knebel 
and Murray, 2012) and has been shown to be disrupted in schizophrenia (Spencer et al., 2003; 
Spencer et al., 2004; Foxe et al., 2005). 
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1.4 Approaching the assessment of the emotional effects  
 of psilocybin and ketanserin 
1.4.1 Overview of the goal and methodological approaches of the emotional experiments
In the previous chapters I have shown that a crucial goal of this thesis is to gain insights into 
the effect of psilocybin on emotional processing and to elucidate the contribution of the 5-HT2A 
receptor to emotional processing. These insights might help us to identify possible mechanism 
implicated in the pathophysiology and treatment of mood disorders and the putative anti-
depressive effect of psilocybin. 
To this end, the effect of psilocybin on the emotional processing bias in emotional face recog-
nition, goal-directed behaviour and mood states was assessed in 17 healthy human subjects 
 using self-report, behavioural and neurophysiological measurements. The specific contribution 
of the 5-HT2A receptors was disentangled by additionally administering the preferential 5-HT2A 
antagonist ketanserin one hour before the administration of psilocybin (see Chapter 2 for details). 
In the following paragraphs, I will explain why assessing the emotional bias in facial recognition, 
goal-directed behaviour and mood states is particularly informative and how these three psycho-
logical domains were operationalised. 
1.4.2 Emotional face recognition
The ability to accurately recognise the emotional state of a person by looking at their facial 
 expression is fundamental for social interaction. In patients with major depression, emotional 
face recognition is biased towards the recognition of negative versus positive emotions (Gur et 
al., 1992; Joormann and Gotlib, 2006; Victor et al., 2010; Elliott et al., 2011), which contributes 
to interpersonal difficulties (Gur et al., 1992) and influences the relapse rate during remission 
episodes (Bouhuys et al., 1999). 
A key role of the serotonergic system in the pathogenesis of this negative bias in facial recog-
nition is, on the one hand, evidenced by genetic studies showing increased attention (Beevers 
et al., 2009) and amygdala response (Hariri et al., 2002; Furmark et al., 2004; Canli et al., 2005; 
Hariri et al., 2005; Heinz et al., 2005) to negative faces in short-allele carriers of the 5-HTTLPR 
polymorphism. On the other hand, various forms of serotonergic manipulations, including 
SSRI (Harmer et al., 2003b; Bhagwagar et al., 2004; Browning et al., 2007; Victor et al., 2010), 
acute tryptophan depletion (ATD) (Murphy et al., 2002; Attenburrow et al., 2003; Harmer et al., 
2003a; Marsh et al., 2006), MDMA (Bedi et al., 2010) and mirtazapine administration (Arnone 
et al., 2009; Rawlings et al., 2010), have been shown to modulate the emotional face recogni-
tion bias. Interestingly, a single dose of SSRIs increased the recognition of negative emotions in 
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most studies (Harmer et al., 2003b; Browning et al., 2007), whereas chronic SSRI administration 
decreased the recognition rate (Harmer et al., 2004). Furthermore, only chronic SSRI adminis-
tration decreased the 5-HT2A  receptor density (Sibille et al., 1997; Meyer et al., 2001; Yamauchi 
et al., 2006), which suggested that changing activity at the 5-HT2A receptors might shift the 
emotional  processing bias in facial recognition. 
To investigate this hypothesis further, we assessed the effect of psilocybin and the preferential 
5-HT2A receptor antagonist ketanserin on the recognition of subtle emotional states from 
the eye regions of the faces of others. We investigated whether subjects exhibited a bias to-
ward the recognition of positive, negative or neutral emotional states. In doing so, we used a 
German version of the “Reading the Mind in the Eyes Test” (Baron-Cohen et al., 2001), but 
adapted the scoring of the test (see Chapter 2 for details) to assess the total number of correct 
recognitions separately for the eye regions of faces depicting positive, negative and neutral 
mental states. 
1.4.3 Emotional goal-directed behaviour
Emotional goal-directed behaviour in social environments requires the selection and inhibition 
of appropriate responses to emotional cues. This process has been operationalised by the emo-
tional go/nogo task, in which subjects must respond to emotional cues with a certain valence 
(e. g., negative) and inhibit response to cues with a different valence (Murphy et al., 1999). The 
performance of this task relies on an prefrontal-limbic network, which comprises the anterior 
cingulated cortex (ACC), the right inferior prefrontal cortex, the amygdala, the orbitofrontal 
 cortex and the insula (Elliott et al., 2000, 2002; Hare et al., 2005; Goldstein et al., 2007; Chiu et 
al., 2008; Schulz et al., 2009; Albert et al., 2011), and regulates the interaction between emotion 
and cognition and the response control processes (Schulz et al., 2009; Disner et al., 2011; Elliott 
et al., 2011). The convergence of these processes may occur during the time range of the N2 and 
P300 event-related potentials, as both potentials are influenced by both the emotional content 
and the inhibitory control over the responses to these cues (Chiu et al., 2008; Krompinger and 
Simons, 2009; Albert et al., 2010; Zhang and Lu, 2012). 
Importantly, performance and neuronal activity in the emotional go/nogo task vary depending 
on the pathological state on the continuum between depression and mania (Murphy et al., 1999; 
Erickson et al., 2005; Kyte et al., 2005; Kaplan et al., 2006; Wessa et al., 2007; Gopin et al., 2011). 
Specifically, in subjects with major depression, the reaction times and/or error rates are biased 
toward negative emotions (Murphy et al., 1999; Erickson et al., 2005; Kyte et al., 2005; Kaplan et 
al., 2006; Wessa et al., 2007), whereas the response pattern in acute mania is strongly biased 
toward positive emotions (Murphy et al., 1999). In depressed subjects, increased activity in the 
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ventral ACC (Elliott et al., 2002) and an increased P300 component (Krompinger and  Simons, 
2009) in response to negative stimuli might underlie the negative emotional processing bias in 
the go/nogo task. 
Alterations in the serotonergic tone have been implicated in the pathogenesis of this negative 
bias by several studies showing that the positive response bias, which is usually observed in 
healthy subjects (Murphy et al., 2002; Erickson et al., 2005; Roiser et al., 2008; Robinson and 
Sahakian, 2009; Feder et al., 2011), is abolished by ATD (Murphy et al., 2002; Roiser et al., 2008; 
Robinson and Sahakian, 2009), most prominently in healthy subjects having first-degree relatives 
with  recurrent or chronic major depression (Feder et al., 2011). 
To assess the influence of psilocybin and 5-HT2A receptor activation on the emotional bias 
in goal-directed behaviour, we used an emotional go/nogo task with positive, negative and 
neutral words as the cues (Murphy et al., 1999; Elliott et al., 2000; Chiu et al., 2008; Elliott et 
al., 2011). Words were used as stimulus material to be able to better differentiate the per-
formance in this task from the emotional face-recognition task. That is, words have a stron-
ger impact on cognitive processes, whereas faces more strongly influence perception (Früh-
holz et al., 2011). In this  respect, the use of words also reduces the possible confounding 
influence of the strong visual effects of psilocybin on emotional processing. Specifically, the 
valences of faces have been suggested to be partially coded by visual features (Calvo and 
 Nummenmaa, 2008) and  configurations (Narme et al., 2011), whereas these visual properties 
do not usually constitute the difference between words with different valences. Therefore, 
a psilocybin-induced disruption in the processing of visual features and configurations is 
 unlikely to alter the differentiation of the valences of words but might influence the differen-
tiation of the valences of faces. To  further  reduce confounding variables, the number of 
letters, syllables, phonemes, frequency of appearance, number of orthographic neighbours 
and imaginability were matched between  different word valences. Finally, the typical emo-
tional go/nogo task was extended by parametrically  manipulating the number of go cues 
 preceding the nogo cues in the trial order from 0 – 6 in each valence condition. This experimen-
tal configuration allows the assessment of sequential emotional facilitatory and inhibitory 
 processes, such as a decrease in RTs with repeated negative stimuli, that have been impli-
cated in the pathophysiology of mood disorders (Joormann, 2004; Goeleven et al., 2006; 
Markus and De Raedt, 2011). Taken together, the emotional valence (pos/neu/neg), the task 
instruction (go/nogo) and the sequential context (0 – 6) were manipulated, and the effects 
of these experimental factors on behavioural (RT and error rates) and  electrophysiological 
(N2 and P300 amplitude) parameters were assessed in psilocybin and ketanserin induced-
states. 
Chapter 1 24
1.4.4 Mood
Alterations in the mood state are a defining psychopathological characteristic of depression and 
mania. Although the mood state is usually not acutely altered by substances that modulate the 
serotonergic tone, such as SSRIs (Harmer et al., 2003b; Bhagwagar et al., 2004; Harmer et al., 
2008) and ATD (Hayward et al., 2005; Robinson and Sahakian, 2009;  Roiser et al., 2009), indol-
amines are known for their acute mood-altering effects (Studerus et al., 2010). Therefore, 5-HT2A 
receptors activation might be more closely linked to the acute mood state than is the serotoner-
gic tone. To further characterise the mood-altering effects of psilo cybin and 5-HT2A agonism, 
we used the clinically relevant rating scale Positive and Negative Affect Schedule (PANAS) to as-
sess the self-reported positive and negative affect (Watson et al., 1988; Krohne, 1996) and the 
State-Trait Anxiety Inventory (STAI) to quantify state-anxiety (Spielberger et al., 1983). 
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1.5  Approaching the assessment of the visual effects  
of psilocybin and ketanserin 
1.5.1 Overview of the goal and methodological approaches of the visual experiments
In the previous chapters I have shown that crucial goals of this thesis are to: elucidate the effects 
of psilocybin on visual processing; disentangle the specific contribution of the 5-HT2A receptor 
to these psilocybin-induced effects; and thereby gain insights into the pathophysiological 
 mechanism underlying visual hallucinations in schizophrenia and Parkinson’s disease. 
To this end, the idea that psilocybin might particularly impair extrastriate visual processing 
functions was addressed in the first visual study by assessing the effects of two different doses 
of psilocybin (125 µg/kg and 250 µg/kg vs. placebo) on the spatiotemporal dynamic of modal 
object completion in 17 subjects using visual-evoked potential recordings in conjunction with 
topographic mapping and source analysis. These effects were then related to the intensity of the 
self-reported psilocybin-induced visual hallucinations, and compared to the previously observed 
deficits in schizophrenia (see Chapter 3 for details). 
To disentangle the specific contribution of the 5-HT2A receptor to the psilocybin-induced 
 effects on visual-evoked potentials in the modal object completion task, we conducted a second 
study in which we pretreated 15 healthy human subjects with the preferential 5-HT2A antagonist 
ketanserin (50 mg) one hour before they received psilocybin (215 µg/kg) (see Chapter 4 for  details). 
The data from the second visual study were additionally used to address the idea that psilo-
cybin might modulate alpha oscillations by 5-HT2A receptor activation, which would lead to a 
change in the visual network excitability that might underlie the formation of visual hallu-
cinations. Therefore, we computed the prestimulus and subsequent visual stimulus-induced 
 parieto-occipital alpha oscillations using single-trial wavelet analysis. These effects were again 
related to the self-reported psilocybin-induced subjective visual effects (see Chapter 4 for details). 
In the following section, I will briefly discuss recent findings on modal object completion, as 
well as on alpha power and phase to infer several hypotheses regarding the effect of psilocybin 
and ketanserin.
1.5.2 Modal object completion
Modal object completion refers to the illusory perception of object boundaries and their 
 en closing surfaces in the absence of any direct sensory information depicting these boundaries 
or surfaces. The ability to interpolate the existence of object surface boundaries is essential 
for accurate object recognition in situations in which only ambiguous or incomplete retinal 
 infor mation of the object is available due to partial occlusion or poor illumination. 
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Which brain areas are responsible for achieving modal completion remains debated, with 
the involvement of the primary visual cortex (V1) being particularly contentious (Seghier and 
Vuilleumier, 2006; Knebel and Murray, 2012). However, a variety of imaging studies provide 
strong evidence that the lateral occipital complex (LOC) and the early visual area V2 are likely to 
play major roles in this process (Hirsch et al., 1995; Ffytche and Zeki, 1996; Mendola et al., 1999; 
Seghier and Vuilleumier, 2006; Knebel and Murray, 2012). Electrophysiological studies addition-
ally indicate that modal completion of simple figures, such as Kanizsa figures, is indexed by the 
modulation of the N170 component (Herrmann and Bosch, 2001; Pegna et al., 2002; Proverbio 
and Zani, 2002; Murray et al., 2004; Spencer et al., 2004; Foxe et al., 2005; Murray et al., 2006; 
Yoshino et al., 2006; Knebel and Murray, 2012), which appears to be driven primarily by the two 
critical processes underlying modal object completion: boundary completion (Murray et al., 
2006) and region-based segmentation (Yoshino et al., 2006). 
Abnormalities in the spatiotemporal brain dynamics of modal object completion have been 
reported in different psychiatric disorders, such as schizophrenia (Spencer et al., 2003; Spencer 
et al., 2004; Foxe et al., 2005), autism (Stroganova et al., 2007) and Williams syndrome (Grice 
et al., 2003). In schizophrenia, disturbances in modal object completion were characterised by 
decrements of the P1 (Spencer et al., 2003; Foxe et al., 2005) and a trend toward reduction 
(Spencer et al., 2003) or significant reduction of the N170 component (Spencer et al., 2004). 
Direct evidence for the involvement of 5-HT2A or 1A receptors in the modulation of visual-evoked 
potentials in general, and modal object completion in particular, is lacking. However, psilocybin 
might modulate modal object completion, as this task relies on extrastriatal visual areas (Hirsch et 
al., 1995; Ffytche and Zeki, 1996; Mendola et al., 1999; Seghier and Vuilleumier, 2006; Knebel and 
Murray, 2012), which appear to be more strongly modulated by psilocybin than the striatal areas 
(see chapter 1.3.4). Understanding the influence of psilocybin and the contribution of 5-HT2A recep-
tor activation on modal object completion is particularly compelling, not only because modal object 
completion is so critical in defining individual perceptual experience but also to elucidate possible 
serotonergic mechanisms implicated in the previously revealed disruptions in modal object comple-
tion observed in schizophrenia (Spencer et al., 2003; Spencer et al., 2004; Foxe et al., 2005).
To elucidate these issues further, we used the data from both visual studies (see above). The 
data from the first visual study served to assess the spatiotemporal dynamics of modal object 
completion. This assessment included the analysis of: (I) the scalp topography, (II) the source 
localisation and (III) the visual-evoked potential waveforms. This combination of analysis meth-
ods has been increasingly used in recent years, as it reduces the experimenter bias associated 
with the selection of an  appropriate time window for the statistical analysis of the components 
(Murray et al., 2008). In brief, during the topographic analysis, the predominant topographies 
(also called the template map) appearing in the normalised, group-averaged ERPs as a func-
tion of time, and experimental condition were identified by means of a spatial k-means cluster 
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analysis (Pascual-Marqui et al., 1994; Brandeis et al., 1995). In a second step, it was statistically 
verified that the maps identified at the group-averaged level also appeared on the individual 
subject level. The extracted time frames of the template maps were subsequently used to calcu-
late the mean amplitude of the P1, N170 and P300 components of the visual-evoked potential. 
Finally, standardised low-resolution electromagnetic  tomography (sLORETA) (Pascual-Marqui, 
2002) was used to estimate the three-dimensional  intra-cerebral current density distributions 
underlying the ERPs within the time frames defined by the topographic analysis. 
1.5.3 Alpha Power and Phase
Alpha oscillations (8–12 Hz) have been identified as a major neural mechanism that regulates by 
inhibition the excitability level of cortical sensory networks (Foxe et al., 1998; Thut et al., 2006; 
Klimesch et al., 2007; Rihs et al., 2007; Romei et al., 2008a; Romei et al., 2008b; Klimesch, 2011; 
Mathewson et al., 2011). This view is supported by the findings that low alpha power is associ-
ated with an increased firing rate of cortical neurons (Haegens et al., 2011) and with an increased 
likelihood to perceive TMS-induced phosphenes (Romei et al., 2008a; Romei et al., 2008b). Fur-
thermore, alpha power decreases in anticipation of (Ergenoglu et al., 2004; Rohenkohl and 
 Nobre, 2011; Stokes et al., 2012) or in response to a visual stimulus (Pfurtscheller et al., 1979; 
Klimesch, 2011), a change that is thought to reflect an adaptation of the excitability level of the 
visual cortical network for the optimal processing of the actual or forthcoming visual input. In 
line with this view, a low prestimulus alpha power is associated on a single-trial basis with an 
increased detection rate of the subsequent visual stimuli (Ergenoglu et al., 2004; Thut et al., 
2006; Hanslmayr et al., 2007; van Dijk et al., 2008; Busch et al., 2009) and with higher visual-
evoked potentials to the visual stimuli (Ergenoglu et al., 2004; van Dijk et al., 2008). Hence, alpha 
oscillations are increasingly recognised as a key mechanism in the regulation of visual per ception. 
Nevertheless, the pharmacological base underlying this crucial role remains largely unknown. 
A possible role of 5-HT2A receptor activation in the modulation of alpha power is indicated 
by the finding that 5-HT2A receptor activation increases the excitability of rat visual cortical 
 networks (Moreau et al., 2010). This 5-HT2A receptor-mediated increase in the excitability might 
be caused by a decrease of alpha power. An increase in the excitability in the absence of direct 
sensory input destabilises the spontaneous network activity, which, according to computational 
models, results in the formation of elementary visual hallucinations (Ermentrout and Cowan, 
1979; Bressloff et al., 2002; Gutkin et al., 2003; Butler et al., 2012). Although this idea has not 
yet been directly tested in humans or animals, several findings are in line with this notion. For 
instance, the geometrical patterns that are produced by these computational models (Ermen-
trout and Cowan, 1979; Bressloff et al., 2002; Gutkin et al., 2003; Butler et al., 2012) are phe-
nomenologically similar to the geometrical elementary visual hallucinations that are produced 
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by indolamine hallucinogens (Klüver, 1966; Siegel and Jarvik, 1975). Furthermore, presenting 
these simple geometrical patterns to anesthetised cats induces patterned neuronal states that 
correspond to the self-organised, spontaneous patterned neuronal states (Kenet et al., 2003). 
Therefore, it has been postulated that a currently undefined inhibitory mechanism is necessary 
to prevent that the usually subliminal spontaneous neuronal activity leads to conscious precepts 
(Billock and Tsou, 2007; Butler et al., 2012). It is conceivable that alpha oscillations mediate this 
inhibition, as alpha oscillations are the key inhibitory mechanism in the visual network. 
Taken together, these findings indicate that psilocybin might decrease alpha power by 5-HT2A 
receptor activation. This decrease of alpha power in the absence of visual stimuli (i.e., before 
stimulus presentation) would cause an increased excitability and therefore might lead to an 
 increase in spontaneously generated neuronal activity that promotes the formation of visual 
 hallucinations. 
To confirm these hypotheses, we used the data from the second visual study (see above) and 
computed the alpha power and phase for the time range before and after the presentation of 
visual stimuli using a single-trial wavelet analysis (see chapter 4 for details). Briefly, the signal of 
each trial and at each time-point in the trial was convoluted with a family of Morlet wavelets. 
Sub sequently, the power in each trial was computed as the sum of the squares of the real and 
imaginary Morlet wavelet components. Furthermore, using the phase information from the 
wavelet analysis, the amount of normalised phase variability across trials was quantified by the 
phase-locking value, PLV (also known as the intertribal coherence (ITC) or phase-locking factor). 
Subsequently, these measures were related to the self-reported intensity of the visual hallucina-
tions quantified by the 5D-ASC questionnaire. 
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2.1 Abstract
Background
Serotonin 1A and 2A receptors have been associated with dysfunctional emotional processing 
biases in mood disorders. These receptors further predominantly mediate the subjective and 
behavioral effects of psilocybin and might be important for its recently suggested antidepressive 
effects. However, the effect of psilocybin on emotional processing biases and the specific contri-
bution of serotonin 2A receptors across different emotional domains is unknown.
Methods
In a randomized double-blind study 17 healthy human subjects received on four separate days 
placebo, psilocybin (215 µg/kg), the preferential 5-HT2A antagonist ketanserin (50 mg), or psilo-
cybin plus ketanserin. Mood states were assessed by self-report ratings, and behavioral and 
event-related potential measurements were used to quantify facial emotional recognition and 
goal-directed behavior towards emotional cues. 
Results
Psilocybin enhanced positive mood and attenuated recognition of negative facial expression. 
Furthermore, psilocybin increased goal-directed behavior towards positive compared to nega-
tive cues, facilitated positive but inhibited negative sequential emotional effects and valence-
dependently attenuated the P300 component. Ketanserin alone had no effects but blocked the 
psilocybin-induced mood enhancement and decreased recognition of negative facial expression.
Conclusion
This study shows that psilocybin shifts the emotional bias across various psychological domains 
and that activation of 5-HT2A receptors is central in mood regulation and emotional face recog-
nition in healthy subjects. These findings may not only have implications for the pathophysiology 
of dysfunctional emotional biases, but may also provide a framework to delineate the mecha-
nisms underlying psylocybin's putative antidepressant effects.
2.2 Introduction
Central components in the pathophysiology of mood disorders are biases towards the processing 
of negative compared to positive emotions across different psychological domains including per-
ception, attention and behavior. For example, depressed subjects need more intensely happy 
facial expression to correctly label happiness (1) and are slower in responding to positive but not 
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to negative words in emotional go/nogo tasks (2,3). A crucial role for serotonin (5-HT) in the 
regulation of emotional biases is evidenced by genetic and pharmacological studies, while the 
differential contribution of 5-HT subreceptors across psychological domains in humans is less 
well-understood (4,5). However, accumulating evidence suggests that 5-HT1A and 2A receptors 
are particularly implicated in the pathophysiology of dysfunctional emotional biases, because 
5-HT1A and 5-HT2A receptor densities are altered in depressive (6–10), bipolar (11,12), and 
anxiety disorder (13,14). In line with this view, 5-HT1A receptor agonists such as buspirone or 
pindolol have been particularly used as add-on treatment to enhance the antidepressant effect 
of SSRIs (7). More recently, also preferential 5-HT2A receptor agonists revealed anxiolytic and 
antidepressive effects in different animal models of mood disorders (15–21). In humans activa-
tion of 5-HT2A receptors has been identified as the primary mechanism underlying the acute 
subjective effects of classical psychedelics such as psilocybin (22), which, at low to medium dos-
es, are predominantly characterized by heightened mood and visual disturbances (23–25). Fur-
thermore, psilocybin induces neuronal activity and neuroplastic effects in prefrontal-limbic cir-
cuits implicated in mood disorder (24). These findings suggest that psilocybin, whose bioactive 
metabolite psilocin activates 5-HT2A, 1A and 2C receptors (26,27), may not only produce acute 
mood enhanging effects but may also induce sustained antidepressant or anxiolytic effects (24). 
In support of this view, a gradual reduction of depressive symptoms and trait anxiety over six 
month was observed after a single dose of psilocybin in a recent placebo-controlled pilot study 
in terminal cancer patients (28).
Taken together, these findings suggest that psilocybin might bias emotional processing away 
from negative information by activating 5-HT1A, 5-HT2A receptors or both receptors. Assessing 
this hypothesis might help to unravel the psychopharmacological mechanism underlying the 
pathophysiology of dysfunctional emotional biases and the recently proposed antidepressant 
and anxiolytic potential of psilocybin. 
To this end, here we investigated for the first time the effect of psilocybin on emotional 
 processing biases across psychological domains. We also disentangled the specific contribu-
tion of the 5-HT2A receptor by antagonizing it with ketanserin. First, we assessed behaviorally 
the ability to recognize the emotional state of another person from facial cues, which has been 
 previously shown to be biased towards negative emotions in depressed and anxious subjects 
(1, 29 –31) and to be related to serotonergic tone (29 –33). Second, response selection and 
 inhibition to emotional cues were quantified by behavioral and event-related EEG measure-
ments in an emotional go/nogo task (2). These are crucial components of goal-directed 
 behavior in social environments (34) and are regulated by the 5-HT system (35 –37). Finally, 
we evaluated and quantified acute psilocybin-induced mood effects using clinical relevant 
 rating scales.
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2.3 Methods and Materials
2.3.1 Subjects
Seventeen healthy right-handed subjects (11 males, 6 females, mean age 26.0 ± 4.36 years, 
15 university students/graduates, 1 highschool diploma, 1 apprenticeship) were recruited 
through advertisement from the University of Zurich. All subjects were healthy according to 
physical examination, including electrocardiography and detailed blood analysis. The Mini-Inter-
national Neuropsychiatric Interview MINI-SCID (38), the DIA-X diagnostic expert system (39), 
and the Hopkins Symptom Checklist SCL-90-R (40) were used to exclude subjects with present 
or antecedent psychiatric disorders or a history of major psychiatric disorders in first-degree 
relatives. The absence of drug dependence or present drug abuse was verified by urine drug-
screening and a self-report drug use questionnaire. Seven subjects reported having previous 
 experiences with psilocybin or other hallucinogens (mean lifetime experiences 2.4 ± 1.1 times) 
and three subjects with MDMA (mean lifetime experiences 3.3 ± 2.5 times). Eight subjects 
 reported to have rarley or sporadically used cannabis (< 4 joints/month).
Subjects were informed by a written and oral description about the procedures of the study, 
including that they will receive on each experimental day in a double-blind manner two sub-
stances, either placebo + placebo, placebo + psilocybin, ketanserin + placebo or ketanserin + psi-
locybin. Furthermore, they were informed about the possible risk of psilocybin administration 
and the broad spectrum of its consciousness altering effects that may range from alterations in 
sensory perception, mood, thought and the experience of self. To minimize the influence of the 
individual’s expectations we emphasized that the psychological effect of psilocybin is known to 
vary largely between and within subjects. The study was approved by the ethics committee of 
the Canton of Zurich. The use of psilocybin in humans was authorized by the Swiss Federal Office 
of Public Health, Department of Pharmacology and Narcotics, Bern, Switzerland.
2.3.2 Experimental design
Using a double-blind within-subject placebo-controlled randomized design subjects received on 
4 experimental days, separated from each other by at least 2 weeks, placebo or ketanserin (50 
mg) (pretreatment) followed after 1 h by placebo or psyilocybin (215 µg/kg) (treatment). These 
specific doses were chosen, because they have previously been shown to effectively induce or 
block the associated changes in conscious states, respectively (41). The time delay between pre-
treatment and treatment was 1 h to ensure maximal 5-HT2A receptor occupancy. Experiments 
started approximately 130 min after treatment and self-report questionnaires were given 360 
min posttreatment to retrospectively rate their subjective experience since drug intake.
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2.3.3 Acute subjective drug effects
The Five Dimensions of Altered States of Consciousness (5D-ASC) questionnaire (42), a self-rating 
scale with 94 visual analogue items, was used to quantify the subjective psychological effects of 
psilocybin. Eleven subscales were recently constructed (43). Of primary interest in regard to the 
current study was the “Blissful State” subscale measuring experiences of pleasure, peace and 
love and the “Anxiety” subscale quantifying anxiety associated with derealisation and deperson-
alization. The German version of the Positive and Negative Affect Schedule (PANAS) was used to 
assess the self-reported positive and negative affect (44,45) and the German version of State-
Trait Anxiety Inventory (STAI) was used to quantify state-anxiety (46). 
2.3.4 Facial emotional recognition
The accuracy of inferring emotional states from the eye region was measured by a German adap-
tation of the “Reading the Mind in the Eyes Test” (47). Briefly, 36 black-and-white photographs 
of the eye region of persons expressing different subtle emotional states (eg. ashamed) were 
presented on a computer screen together with four words describing the states of the persons. 
Participants were instructed to choose the word which described the state of the person most 
accurately. The total number of correct recognitions was computed for different valence catego-
ries (positive, negative and neutral). Because the previously used valence categorization (48) was 
based on a small sample of 12 undergraduate women who rated the picture in combination with 
the target word, pictures and target/distracter words were rerated seperately in a study compris-
ing 40 subjects (Supplementary information). 
2.3.5	 Emotional	go/nogo task
In the emotional go/nogo task, emotionally valenced words (positive, negative, neutral) were 
presented in easy readable font (“Universe”) in the middle of the computer screen. We used 
emotional words as stimulus material because they have, in contrast to faces, a stronger impact 
on cognitive versus perceptual processes (49) and therefore allow better differentiation of the 
performance in the emotional go/nogo from the facial recognition task. Participants were in-
structed by text appearing at the beginning of each block to press as rapidly as possible a re-
sponse bottom when words of one valence category are presented (“go” cues) and withhold 
responses to words of another valence category (“nogo” cues). The following blocks were pre-
sented once in the first and once in the second half of the experiment in a randomized order: 
(1) positive go, neutral nogo, (2) positive go, negative nogo, (3) neutral go, positive nogo, (4) 
neutral go, negative nogo, (5) negative go, positive nogo, (6) negative go, neutral nogo. Each 
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block contained a pseudoranomized presentation of 30 go trials and 10 nogo trials, resulting in 
a total of 360 go trials and 120 nogo trials. To enable a parametric assessment of sequential 
facilatory and inhibitory processes, the number of go cues preceding nogo cues in the trial or-
der was counterbalanced in all blocks from 0 to 6 according to previous studies (34). In each 
trial, words were presented for 280 ms followed by a fixation cross, which was used to reduce 
eye movements. The presentation time of the fixation cross was randomized from 1200 to 1400 
ms to discourage anticipatory responses. Words were taken from the Berlin Affective Word List 
Reloaded (50) and were matched for number of letters, syllables, phonemes, frequency of ap-
pearance, number of orthographic neighbors and imageability. Furthermore, negative and pos-
itive words were matched for arousal but differed in valence ratings (Supplementary informa-
tion).
2.3.6 Electroencephalogram recording
Electroencephalogram (EEG) recordings were made using Bio-Semi (Amsterdam, The Nether-
lands) ActiveTwo electrode system with 64 scalp electrodes. Additional electrodes were attached 
on the outer canthus of each eye to record the horizontal electrooculogram and infraorbitally 
and supraorbitally to the left eye to record the vertical electrooculogram. Electrophysiologic sig-
nals were digitized at 512 Hz.
2.3.7 EEG analysis
EEG data were high-pass filtered at 0.5 Hz to attenuate channel drifts. Bad channels were inter-
polated using spherical splines (51), and eye movements and blinks were removed by applying 
the extended infomax ICA algorithm (52,53). EEG data were low-pass filtered at 30 Hz. All trials 
(correct and incorrect) were segmented separately for each valance go/nogo combination from 
-200 to +1200 ms relative to stimulus presentation. To avoid remaining artifacts in further analy-
sis, segments with activity exceeding ±75 µV in any channel, gradients of 50 µV/s and activity 
below 0.5 µV for at least 100 ms were excluded from further analysis before averaging. ERPs 
were rereferenced to the average reference before N2 and P300 amplitudes were quantified 
against baseline activity. Peak amplitudes were obtained from the 4 midline electrodes that re-
vealed highest amplitudes across all drug conditions. The N2 was therefore defined as the most 
negative peak from 250–450 ms at electrode AFz, Fz, FCz, Cz, and the P300 was defined as the 
most positive peak from 450–700 ms at FCz, Cz, CPz, Pz (Figure S1 in Supplementary informa-
tion).
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2.4 Results
2.4.1 Acute subjective effects
PANAS
Repeated-measures analysis of variance (ANOVA) with pretreatment, treatment and subscale 
as within-subject factors revealed that psilocybin significantly increased PANAS scores 
(F(1, 16) = 16.608, p < 0.001, ηp2= 0.509). Importantly, the triple interaction between pretreat-
ment × treatment × subscale (F(1,16) = 21.160, p < 0.001, ηp2= 0.569) showed that psilocybin 
 significantly increased positive affect subscale after pretreatment with placebo (p < 0.00001) 
but not ketanserin (p = 1) (Figure 1). In contrast, psilocybin did not increase negative affect, 
neither after pretreatment with placebo (p = 1) nor after pretreatment with ketanserin (p = 1). 
STAI-State
Repeated-measures ANOVA revealed a significant pretreatment × treatment interaction 
(F(1,16)=14.708, p<0.01, ηp2=0.480). Bonferroni-corrected post-hoc analyses of this interaction 
indicated that ketanserin increased STAI scores in placebo- (p<0.01) and psilocybin-treated 
(p<0.000001) subjects. In contrast, psilocybin did not change STAI scores after pretreatment 
with placebo (p=0.515) (Figure 1).
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Figure 1 
Subjective effects of psilocybin and ketanse-
rin as measured by the positive and nega-
tive affect scale (PANAS) and the State-trait 
anxiety inventory (STAI). Values are the 
mean and standard errors of total scores.
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5D-ASC
Psilocybin significantly increased 5D-ASC scores (F(1,16)=78.059, p<1–6, ηp2=0.823) and pre-
treatment with ketanserin reduced this psilocybin-induced increase F(1,16)=87.223, p<1–7, 
ηp2=0.845). Bonferroni-corrected post-hoc analysis on the triple interaction between pretreat-
ment × treatment × subscale (F(10,160)=9.549, p<1–11, ηp2=0.374) indicated that psilocybin 
 increased the blissful state subscale, as well as the experience of unity, insightfulness, complex 
imagery, elementary imagery, changed meaning of percepts (all p’s<1–9), the disembodiment 
(p<1–8), audio-visual synesthesiae (p<0.00001), impaired control and cognition (p<0.001), spir-
itual experience (p<0.01), but not Anxiety (p=1) subscale after pretreatment with placebo. Psi-
locybin did not increase any of these 11 subscales after pretreatment with ketanserin (all p’s=1) 
(Figure 2).
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Figure 2
Subjective effects of psilocybin as measured 
by the 5-Dimension Altered States of Con-
sciousness scale (5D-ASC). Vales are the 
means and standard errors of percentages 
of the total possible scores of the eleven 
subscales of the 5D-ASC. 
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2.4.2 Facial emotional recognition
Error rate
A repeated-measures ANOVA using pretreatment, treatment and valence as within-subject fac-
tors revealed a main effect of valence (F(2, 32) = 16.857, p < 0.0001, ηp2= 0.513). Psilocybin mod-
ulated error rates depending on the valence of the facial expression (F(2, 32) = 5.460, p < 0.01, 
ηp2= 0.254). This interaction between treatment and valence was further modulated by pre-
treatment (F(2, 34) = 3.886, p < 0.05, ηp2= 0.181) because psilocybin increased error rates for 
negative faces only after placebo (p < 0.05) but not ketanserin pretreatment (p = 1) (Figure 3). 
Overall, this interaction indicated a relative enhanced performance for positive compared to 
negative items particulary in the placebo + psilocybin condition (p < 0.00001) and somewhat in 
the ketanserin + psilocybin condition (p < 0.01), but not in the placebo + placebo (p = 0.44) and 
ketanserin + placebo condition (p = 1). A second repeated measure ANOVA on the valence of the 
choosen word using pretreatment and treatment as within subject factors revealed that psilo-
cybin biased to choose higher valenced words (F(1, 16) = 3.667, p = 0.074, ηp2= 0.186) and ketan-
serin lower valenced words (F(1, 16) = 4.040, p = 0.062, ηp2= 0.202) at a trend level.
2.4.3 Emotional go/nogo task
Behavioral results
Reaction time (RT)
RTs for correct responses to go stimuli were subjected to a repeated-measures ANOVA using 
pretreatment, treatment and valence as within-subject factors. RTs were modulated by word 
valence (F(2,32)=31.312, p<1–7, ηp2=0.662). Psilocybin increased RTs (F(1,16)=9.696, p<0.01, 
ηp2=0.378) as a function of word valence (F(2,32)=6.742, p<0.01, ηp2=0.296). Specifically, psilo-
cybin increased reaction time much more for negative (p<1–6) and neutral (p<1–7) than for 
positive words (p<0.01), which indicates a stronger response bias to positive versus negative 
words in psilocybin (p<1–6) than in placebo condition (p<0.05) (Figure 4). Pretreatment with 
ketanserin did not significantly change this psilocybin-induced preferential reaction time for pos-
itive words (F(2,32)=0.860, p=0.433, ηp2=0.051).
Error rate
A repeated-measures ANOVA on error rates with pretreatment, treatment, go/nogo, and valence 
as within-subject factors showed a main effect of valence (F(2,32)=14.949, p<0.0001, ηp2=0.480) 
and go/nogo condition (F(1,16)=25.001, p<0.001, ηp2=0.610). Psilocybin increased error rates 
(F(1,16)=18.640, p<0.001, ηp2=0.5381) depending on word valence (F(2,32)=3.624, p<0.05, 
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Figure 3
Effect of psilocybin and ketanserin on error 
rates in recognizing positive, neutral and 
negative facial expressions. Values are the 
means and standard errors.
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Effect of psilocybin and ketanserin on RTs 
towards positive, neutral and negative cues 
in the emotional go/nogo task. Values are 
the means and standard errors.
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ηp2=0.185), but irrespective of go/nogo condition (F(1,16)=0.112, p=0.742, ηp2=0.007). Specifi-
cally, psilocybin significantly increased error rates only for neutral (p<0.01) but not for positive 
(p=1) or negative (p=1) words (Figure 5). Furthermore, error rates were higher for negative 
compared to positive stimuli after psilocybin (p<0.05) but not placebo administration (p=0.40). 
These valence-specific effects of psilocybin on error rates did not differ between the go and nogo 
condition (F(2,32)=1.643, p=0.209, ηp2=0.093) and were not altered by ketanserin pretreat-
ment (F(2,32)=0.887, p=0.422, ηp2=0.053). 
Sequential effects
To assess sequential effects, RTs for correct responses to go stimuli were subjected to a repeated-
measures ANOVA using pretreatment, treatment, valence and number of repetition as within-
subject factors. RTs decreased with increasing number of repetition (F(5,80)=2.677, p<0.05, 
ηp2=0.143), which was valence-specific (F(10,160)=5.501, p<0.00001, ηp2=0.256). Subsequent 
Bonferroni-corrected post-hoc analyses showed that RTs to go stimuli was decreased for the 
sixth repetition (maximal repetition) of positive (p<0.01) and neutral (p<0.01) but not negative 
go stimuli (p=0.10) compared to zero repetition (minimal repetition). Interestingly, psilocybin 
modulated these sequential emotional effects, which is indicated by the significant triple interac-
tion between treatment × valence × number of repetition (F(10,160)=2.500, p<0.01, ηp2=0.135). 
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Effect of psilocybin and ketanserin on 
error rates in responding towards posi-
tive, neutral and negative cues in the 
emotional go/nogo task. Values are the 
means and standard errors
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Specifically, the decrease in RTs between 0 and 6 repeating positive trials reached Bonferroni-
corrected significance after treatment with psilocybin (p<0.001) but not placebo (p=1), while a 
significant increase of RTs between 0 and 6 repeating negative trials were observed after psilocy-
bin (p<0.01) but not placebo treatment (p=1) (Figure 6). 
Electrophysiological results
N2
A repeated measures ANOVA on the N2 amplitude with pretreatment, treatment, go/nogo, va-
lence and electrode as within-subject factors revealed higher N2 amplitudes for neutral com-
pared to negative (p<0.05) and positive (p<0.05) stimuli (F(2,32)=5.036, p<0.05, ηp2=0.239) 
and higher amplitude for nogo compared to go stimuli (F(1,16)=20.073, p<0.001, ηp2=0.556). 
Psilocybin attenuated the N2 amplitude (F(1,16)=5.230, p<0.05, ηp2=0.246) independent of the 
word valence (F(2,32)=2.538, p=0.094, ηp2=0.137) and the go/nogo condition (F(1,16)=0.701, 
p=0.415, ηp2=0.042). 
P300
A repeated measure ANOVA using pretreatment, treatment, go/nogo, valence and electrode 
as within-subject factors revealed higher P300 amplitudes for positive (p < 1– 6) and negative 
Figure 6
Effect of psilocybin and ketanserin on se-
quential emotional RT effects in the emo-
tional go/nogo task. Depicted are differ-
ences in RTs (means and standard errors) 
between the conditions with minimal (zero 
repetition) and maximal repetitions (six 
repetitions) of positive, neutral and nega-
tive cues. 
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(p < 1–7) compared to neutral stimuli (F(2, 32) = 29.740, p < 1–7, ηp2= 0.650) and higher ampli-
tudes for nogo than for go stimuli (F(1, 16) = 117.689, p < 1– 8, ηp2= 0.880). Psilocybin decreased 
the P300 amplitude (F(1, 16) = 15.323, p < 0.01, ηp2= 0.483) depending on pretreatment condi-
tion (F(1, 16) = 4.646, p < 0.05, ηp2= 0.225). Bonferroni-corrected post-hocs showed that psilocy-
bin decreased the P300 amplitude only after pretreatment with placebo (p < 0.01) but not ket-
anserin pretreatment (p = 1). Importantly, the psilocybin-induced decrease was dependent on 
the word valence (F(2, 32) = 3.94, p < 0.05, ηp2= 0.198) because the decrease was most pro-
nounced for neutral (p < 1–13, -0.97 µV) followed by negative (p < 1–12, -0.85 µV) and positive 
(p < 1–10, -0.71 µV) words. The significant triple interaction between pretreatment × treatment 
× valence (F(2, 32) = 4.164, p < 0.05, ηp2= 0.207) revealed the complex nature of the drug effects 
on the emotional processing. Specifically, during placebo+placebo condition Bonferroni-cor-
rected post-hocs indicated higher P300 amplitudes for negative compared to neutral words 
(p < 0.001). In contrast in the placebo + psilocybin condition the positive stimuli evoked higher 
P300 amplitudes compared to neutral stimuli (p < 0.05). The strongest effect were seen in the 
ketanserin + psilocybin condition because P300 amplitude were much higher for positive 
(p < 0.00001) and negative stimuli (p < 0.00001) compared to neutral stimuli (Figure 7). 
Figure 7
Effect of psilocybin and ketanserin on the 
group-averaged event related potential 
waveforms in response to positive (black 
traces), negative (red traces) and neutral 
stimuli (grey traces) averaged from FCz, Cz, 
CPz and Pz electrode sites, where P300 
 amplitude was most pronounced. The box 
indicates the time-range of the P300 com-
ponent.
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2.5 Discussion
Our data show that psilocybin biases emotional processing towards positive relative to negative 
information, an effect that is consistent across different psychological domains. Specifically, psi-
locybin first enhanced positive mood states, second decreased recognition of negative facial ex-
pression, and third increased behavior towards positive relative to negative cues. In contrast to 
these generalized effects of the serotonergic agonist psilocybin, a more specific role for 5-HT2A 
receptors in elevating mood and attenuating the recognition of negative facial expression is indi-
cated by the finding that the preferential 5-HT2A antagonist ketanserin blocked these psilocybin-
induced effects.
2.5.1 Mood states
Psilocybin predominantly enhanced positive mood states, as evidenced by the marked in-
crease in the “positive affect” but not “negative affect” subscale scores of the PANAS ques-
tionnaire, as well as by the increase in “blissful” but not “anxiety” subscale scores of the 5D-
ASC questionnaire. These strong effects of psilocybin on mood contrasts with the usually 
lacking acute mood effects of drugs that modulate the serotonergic tone such as acute tryp-
tophan depletion (30, 35, 54) or selective serotonin reuptake inhibitors (SSRI) administration 
(31, 32, 55). This apparent disparity suggests that a specific activation of certain 5-HT subre-
ceptors is necessary to acutely enhance mood. Indeed, the finding that the preferential 
5-HT2A antagonist ketanserin blocked the mood enhancing effects of psilocybin suggests that 
5-HT2A receptors are implicated in regulating positive mood states. Moreover, we argue that 
the additional stimulation of 5-HT1A or 5-HT2C receptors by psilocybin is rather unlikely to 
contribute to the mood effects of psilocybin, because ketanserin has nearly no affinity to 
5-HT1A receptors and about 50 fold higher affinity to 5-HT2A compared to 5-HT2C receptors 
(Psychoactive Drug Screening Program [PDSP]: http://pdsp.med.unc.edu). Furthermore, the 
5-HT2B/2C agonist meta-Chlorphenylpiperazin (mCPP) induces anxiety rather than positive 
mood states (56). Finally, it is unlikely that expectation of receiving psilocybin considerably 
contributed to the mood effects, because various drug combinations were administrated in a 
double-blind procedure and subjects were instructed that the psychological effects of psilo-
cybin varies largely between and within subjects. 
2.5.2 Facial emotional recognition
Serotonin 2A receptors appear also to be crucially involved in the recognition of negative facial 
expressions, because ketanserin blocked psilocybin-induced attenuation in recognizing negative 
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emotional states from the eye region of human faces. This finding is in line with the central role 
of serotonin in emotional facial recognition as previously established by pharmacological (29–
33) and genetic studies (57), but extends this notion by showing that specific activation of 5-HT2A 
receptors likely biases facial recognition away from negative emotion. This mechanism might 
also contribute to the attenuated recognition of negative facial expression as previously ob-
served after single dose of 3,4-Methylenedioxymethamphetamine (MDMA)(33) and after chron-
ic administration of SSRIs (29,58), because MDMA has a moderate affinity at 5-HT2A receptors 
(59) and chronic SSRI administration changes 5-HT2A receptor density (60,61). 
2.5.3 Goal-directed behavior
In the emotional go/nogo task psilocybin enhanced the response bias towards positive relative 
to neutral and negative emotional stimuli, which was evidenced at the behavioral level by the 
psilocybin-induced increase in reaction times to negative and neutral compared to positive stim-
uli. In addition, this response bias was modulated by the sequential context of the stimuli across 
all drug conditions, an effect that was augmented by psilocybin administration. That is, across all 
drug conditions sequential repetition of positive and neutral stimuli facilitated processing (62, 
63), as indicated by decreased reaction times to positive and neutral stimuli. Interestingly, this 
sequential facilatory effect was lacking after negative stimuli, a finding that has not yet been re-
ported in emotional go/nogo tasks but was previously observed in semantic (64,65) and negative 
affective priming tasks (66–68). Given that this lacking facilitation has been interpreted as an 
inhibition of negative concepts within the attentional (66) or memory system (65), and that psi-
locybin prolonged reaction time for repeated negative stimuli but decreased it for repeated pos-
itive stimuli, psilocybin may also increase inhibition of negative relative to positive concepts in 
the attentional or memory system. 
Support for such a psilocybin-induced shift in the attentional system was revealed by the effect 
of psilocybin on event-related potentials. The event-related potentials analysis indicated that 
across all drug conditions, the word valence affected early and late response-selection, inhibition 
and attention processes as indexed by the decreased N2 and enhanced P3 component for emo-
tional relative to neutral stimuli (69,70). Most importantly, while psilocybin and ketanserin did 
not modulate these valence-specific effects during the N2 time-range, psilocybin strongly de-
creased the P300 component in all valence conditions, and particularly for negative and neutral 
stimuli. Because this valence-dependent P300 decrease was equally present in both the go and 
nogo condition, it is conceivable that this psilocybin-induced change in emotional processing is 
neither specific for response selection (go) nor for inhibition (nogo), but rather reflects a more 
general process underlying the P300. For instance, the P300 amplitude is strongly modulated by 
the amount of attentional resource allocation (71), and several behavioral studies previously 
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showed that psilocybin attenuates attentional performance (41,72,73). This suggests on the one 
hand that the strong psilocybin-induced decrease of the P300 seen across all valence conditions 
might reflect an important electrophysiological index of the previously reported psilocybin-in-
duced attentional deficits. On the other hand, the small valence-dependent decrease suggests 
that psilocybin may attenuate the allocation of attentional resources to neutral and negative 
stimuli more strongly than to positive stimuli, which results in a relative positive attentional bias.
Contrary to the crucial contribution of 5-HT2A receptors in modulating mood states and emo-
tional face recognition, the psilocybin-induced relative bias towards the processing of positive 
emotions in the go/nogo task were not blocked by pretreatment with ketanserin. Thus the psilo-
cybin-induced emotional bias might rather be due to a stimulation of 5-HT1A or 5-HT2C receptor 
than 5-HT2A receptors. However, the strong valence-independent reduction of the P300 seen 
after psilocybin administration was partially reversed by ketanserin, indicating an involvement of 
5-HT2A receptors in the valence-independent attentional performance. 
2.5.4 Implication for mood disorders
In the present study psilocybin produced behavioral and electrophysiological effects that were 
opposite to the dysfunctional emotional processing bias seen in depressed subjects in emotional 
facial recognition (1,29–31), goal-directed behavior (2,3,70) and mood states. For example, in 
the emotional go/nogo task psilocybin increased RTs and decreased P300 amplitudes particulary 
for negative and neutral stimuli, while depressed subjects were delayed in responding to positive 
cues (2,3) and displayed increased P300 component for negative stimuli (70). Thus it appears 
that psilocybin may have the potential to acutely shift dysfunctional emotional biases in depres-
sion. Such an acute shift might in conjunction with the reported effect of psilocybin on neuro-
plastic factors (24) lead to sustained adaptations and may therefore account for the discussed 
antidepressive potential of psilocybin-like compounds (24,28). Hence, further studies using dif-
ferent and multiple doses of psilocybin are indicated to explore, whether the effect of psilocybin 
on emotional biases are dose-dependent and whether psilocybin may shift the negative emo-
tional biases seen in depression. 
Furthermore, here we identify 5-HT2A receptors activity as a potential crucial pharmacologi-
cal target in the treatment of negative mood states and negative emotional facial recognition 
bias. In line with this finding, negative mood is associated with pessimistic attitudes (74) and 
medication-free major depression patients with high pessimistic attitudes have increased 5-HT2A 
receptor binding in the prefrontal cortex compared to healthy controls (8–10). Furthermore, 
chronic administration of SSRIs does not only shift negative mood states and negative bias in fa-
cial recognition in depressed patients (29,58) but also seems to normalize alterations in 5-HT2A 
receptor densities in depressed subjects (60,61). 
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In sum, the present study indicates that the assessment of the effects of psilocybin provides a 
valuable framework to identify neuropsychopharmacological mechanisms underlying dysfunc-
tional emotional biases and the putative antidepressant effects of psilocybin and related com-
pounds.
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2.9 Supplemental Information
Supplemental Methods
Study on the “Reading the Mind in the Eyes Test”
In a study involving 40 subjects (20 men, 20 female, mean age 27) the 36 pictures were pre-
sented without target and distracter words and subjects rated the picture on the 9-point Self-
Assessment Manikin (SAM) scale (1). These rating scores were subjected to a one-sample t-test. 
Pictures with ratings significantly (p<0.05) below neutral (=5) were categorized as negative and 
pictures and ratings significantly (p<0.05) above neutral as positive, while pictures that did not 
reach significance belonged to the neutral category. Additionally, all words (target and distract-
ers) were presented on a second occasion without pictures and subjects rated the words using 
again the SAM scale. These values were used to assess whether the valence of the chosen word 
was significantly modulated by the pharmacological manipulations.
Table S1. Ratings of the “Reading the Mind in the Eyes Test”
Item No. Valence Rating Score Standard Deviation Standard Error t-value p
2 negativ 2.275000 1.085747 0.171672 -15.8733 0.000000
26 negativ 2.725000 1.300641 0.205649 -11.0625 0.000000
8 negativ 3.125000 1.380960 0.218349 -8.5872 0.000000
32 negativ 3.475000 1.552294 0.245439 -6.2134 0.000000
22 negativ 3.475000 1.518898 0.240159 -6.3500 0.000000
35 negativ 3.475000 1.154423 0.182530 -8.3548 0.000000
5 negativ 3.600000 1.428645 0.225889 -6.1977 0.000000
33 negativ 3.725000 1.449801 0.229234 -5.5620 0.000002
14 negativ 4.000000 1.414214 0.223607 -4.4721 0.000065
17 negativ 4.075000 1.308503 0.206892 -4.4709 0.000065
4 negativ 4.400000 0.955416 0.151065 -3.9718 0.000298
23 negativ 4.550000 1.060962 0.167753 -2.6825 0.010661
31 neutral 4.575000 1.646870 0.260393 -1.6321 0.110698
9 neutral 4.675000 1.227620 0.194104 -1.6744 0.102062
24 neutral 4.675000 1.558887 0.246482 -1.3186 0.195009
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29 neutral 4.675000 1.474353 0.233116 -1.3942 0.171163
27 neutral 4.700000 1.362501 0.215430 -1.3926 0.171642
18 neutral 4.775000 1.790108 0.283041 -0.7949 0.431461
19 neutral 4.775000 1.458617 0.230628 -0.9756 0.335276
11 neutral 4.775000 1.761228 0.278475 -0.8080 0.424007
28 neutral 4.875000 1.635935 0.258664 -0.4833 0.631619
36 neutral 4.875000 2.065436 0.326574 -0.3828 0.703975
7 neutral 4.975000 1.404891 0.222133 -0.1125 0.910968
34 neutral 5.075000 1.926702 0.304638 0.2462 0.806824
12 neutral 5.175000 1.430214 0.226137 0.7739 0.443675
13 neutral 5.225000 1.731866 0.273832 0.8217 0.416259
25 neutral 5.375000 1.563814 0.247261 1.5166 0.137428
16 positiv 5.600000 1.104768 0.174679 3.4349 0.001420
10 positiv 5.675000 1.347124 0.212999 3.1690 0.002972
30 positiv 5.900000 1.549193 0.244949 3.6742 0.000715
3 positiv 6.075000 1.327954 0.209968 5.1198 0.000009
15 positiv 6.100000 1.410583 0.223033 4.9320 0.000016
6 positiv 6.200000 1.264911 0.200000 6.0000 0.000001
21 positiv 6.250000 1.372813 0.217061 5.7588 0.000001
1 positiv 6.275000 1.484752 0.234760 5.4311 0.000003
20 positiv 6.800000 1.223698 0.193484 9.3031 0.000000
Table S2. Characteristics of affective words in the go/nogo task
positiv negativ neutral
Number of letters 6.4 ± 1.5 6.3 ± 1.5 6.6 ± 1.4
Syllables 2.1 ± 0.7 2.0 ± 0.7 2.2 ± 0.6
Phonems 5.7 ± 1.4 5.6 ± 1.5 5.8 ± 1.4
Frequency of appearance per million words 50.4 ± 57.5 40.2 ± 65.5 48.7 ± 83.5
Number of orthographic neighbors 1.5 ± 2.2 1.6 ± 2.2 2.1 ± 2.6
Imageability 4.1 ± 1.2 3.9 ± 1.0 3.4 ± 1.3
Arousal 3.2 ± 0.6 3.5 ± 0.6 1.9 ± 0.3
Valence 2.2 ± 0.3 -2.1 ± 0.3 0.0 ± 0.3
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Electroencephalography Analysis
Supplemental Results
Differences between go and nogo condition in the N2 and P3 scalp topography
Repeated measure analysis of variance (ANOVA) on the N2 amplitude revealed no significant 
 interaction between electrode and go/nogo condition (F(3,48)=0.959, p=0.420, ηp2=0.057) and no 
significant triple interaction between electrode × go/nogo condition × treatment (F(3,48)=0.662, 
p=0.580, ηp2=0.040). However, repeated measure ANOVA on the P300 amplitude revealed a 
significant interaction between electrode and go/nogo condition (F(3,48)=27.336, p<1–9, 
ηp2=0.631), indicating that the nogo compared to the go stimuli induced a more anterior P300 
distribution. Psilocybin did not modulate this topographic difference because the interaction be-
tween electrode × go/nogo condition × treatment did not reach significance (F(3,48)=0.245, 
p=0.865, ηp2=0.015). 
Supplemental References
 1.  Lang PJ (1980): Behavioral treatment and bio-behavioral assessment: Computer applications. In Sidowski JB, 
Johnson JH, Williams TA, editors. Technology in Mental Health Care Delivery Systems. Norwood, NJ: Ablex, 
119–137.
A) B)Figure S1. Display of the scalp electrode 
sites used in the event-related potential 
analyses. A) Highlighted in black are the 
electrodes AFz, Fz, FCz and Cz that were 
used for the N2 peak measurements. B) 
Highlighted in black are the electrodes FCz, 
Cz, CPz and Pz that were used for the P300 
peak measurements. 
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3.1 Abstract
Background 
Recent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors 
are implicated in visual processing and possibly the pathophysiology of visual disturbances 
 including hallucinations in schizophrenia and Parkinson’s disease. 
Methods
To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucino-
genic 5-HT2A/1A agonist psilocybin (125 μg/kg and 250 μg/kg vs placebo) on the spatiotemporal 
dynamics of modal object completion was assessed in normal volunteers (n=17) using visual 
evoked potential (VEP) recordings in conjunction with topographic-mapping and source-analysis. 
These effects were then considered in relation to the subjective intensity of psilocybin-induced 
visual hallucinations quantified by psychometric measurement. 
Results
Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the P1 com-
ponent selectively over occipital electrode sites. The decrease of the N170 was most apparent 
during the processing of incomplete object figures. Moreover, during the time period of the 
N170 the overall reduction of the activation in the right extrastriate and posterior parietal areas 
correlated positively with the intensity of visual hallucinations.
Conclusions
These results suggest a central role of the 5-HT2A/1A-receptors in the modulation of visual 
 processing. Specifically, a reduced N170 component was identified as potentially reflecting a 
key process of 5-HT2A/1A receptor-mediated visual hallucinations and aberrant modal object 
completion potential. 
3.2 Introduction
Despite the fact that the visual and serotonergic systems are among the most explored research 
topics in neuroscience, there is sparse information about the role of serotonin (5-HT) in visual 
 processing. However, the high expression of the 5-HT1A (1,2) and 5-HT2A receptors (3–5) in the 
visual areas V1, V2, V3 and lateral suprasylvian cortex (LS) suggest a central role of the 5-HT1A and 
2A receptors in visual processing. Furthermore, 5-HT2A receptors have been implicated in the 
pathogenesis of visual hallucinations in Parkinson’s (6–8) and schizophrenic patients (9). In support 
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of this view, visual hallucinations in Parkinson’s patients have been associated with increased 
 density of 5-HT2A receptors in cortical visual pathways (6,8) and effectively treated with the 
5-HT2A receptor inverse agonist pimavanserin (7). Moreover, visual disturbances and hallucina-
tions induced by the indoleamine hallucinogen psilocybin are predominantly mediated by the 
5-HT2A receptor (10) and resemble, in phenomenological (11) and behavioural measurements 
(12), visual disturbances found in schizophrenia (13, 14). Hence, there is an increasingly recognized 
role for the 5-HT2A receptors in the pathogenesis of visual hallucinations, while the brain mecha-
nisms mediating between 5-HT2A receptor activation and visual hallucination are still unknown. 
To further characterize the role of the 5-HT2A/1A receptors in visual processing and to eluci-
date possible pathophysiological mechanisms of visual deficits and hallucinations, we assessed 
the effect of the mixed 5-HT2A/1A agonist psilocybin (125 µg/kg and 250 µg/kg vs. placebo) 
in healthy volunteers. Electroencephalographic recordings were made while participants 
viewed Kanizsa- and non-Kanizsa-figures (Figure 1). Behavioural responses were recorded and 
high-density electrical mapping with source-analysis was used. This allowed for measurement of 
the spatiotemporal brain dynamics of visual modal object completion and its association with 
the appearance of visual hallucinations.
Modal object completion refers to the illusory perception of object boundaries and their 
 enclosing surface in the absence of any direct sensory information depicting these boundaries 
or surfaces. The brain’s ability to interpolate the existence of object surface boundaries is essen-
tial for accurate object recognition in situations where only ambiguous or incomplete retinal 
 information of the object is available (i.e. due to partial occlusion or poor illumination). Modal 
completion has been of particular interest to vision scientists as it is critical for the accurate 
perception of objects and the delineation of multiple objects from themselves or their back-
ground. Imaging studies provide strong evidence that the intermediate lateral occipital complex 
(LOC) as well as the early visual area V2 are likely to play a major role in modal completion 
(15 –18), while the involvement of the primary visual cortex is more contentious (19). Electro-
physiological studies revealed that modal object completion of simple figures such as Kanizsa-
figures is predominantly indexed by the modulation of the N170 component (20–25), which ap-
pears to be driven primarily by the two critical processes underlying modal object completion, 
boundary-completion (22) and region-based-segmentation (25). In some previous studies the 
presentation of Kanizsa-figures, compared to control figures, have additionally been associated 
with an enhancement of the earlier P1 (26) and the subsequent closure negativity (Ncl ) compo-
nent (22). However, as the Ncl component is more reliably induced by more complex fragmented 
images and reflects successful recognition of complex images (27, 28) it is unlikely to be as 
 relevant to the processing of the simple Kanizsa-figures used in the current experiment.
The high density of 5-HT1A (1,2) and 5-HT2A (3–5) receptors in LOC and V2, as well as the 
strong activation seen in these areas after psilocybin administration during resting state (29) 
Chapter 3 66
 suggest that psilocybin might influence modal object completion. As these processes are so  critical 
in defining one’s perceptual experience, this study aims to characterize and understand the means 
by which 5-HT2A/1A receptor activity can alter this fundamental aspect of visual experience.
3.3 Methods and materials
3.3.1 Subjects
Healthy right-handed subjects (8 males, 9 females, mean age 28.8 ± 3.5 years) were recruited 
through advertisement from the University of Zurich. All subjects were healthy according to 
physical examination including electrocardiography, hematogram and detailed blood analysis. 
The DIA-X diagnostic expert system (30) and a clinical interview was used to exclude subjects 
with present or antecedent psychiatric disorders, regular alcohol or substance abuse and a his-
tory of major psychiatric disorders in first degree relatives. The screening procedure was supple-
mented by the Freiburg Personality Inventory FPI (31) and Hopkins Symptom Checklist SCL-90-R 
(32) and a self made substance consumption questionnaire. Since the personality trait factor 
“emotional lability” was identified to be a predictor for negative experiences during hallucino-
gen-induced altered states of consciousness (33), scores exceeding the mean value of normative 
FPI data by two SD were also used as exclusion criterion. Twelve participants reported having 
previous experience with psilocybin or other hallucinogens (mean life time experiences 5.5 ± 4.7 
times). None of the subjects consumed any psychoactive substance except alcohol, nicotine, can-
nabis and caffeine more than once a year. 
After being informed by a written and oral description of the procedures of the study and the 
effects and possible risks of PY administration, all volunteers gave written informed consent to 
participate in this study. The study was approved by the ethics committee of the University Hos-
pital of Psychiatry, Zurich, and the use of psilocybin in humans was authorized by the Swiss Fed-
eral Office for public health.
3.3.2 Substance and dosing
Psilocybin was obtained through the Swiss Federal Office for Public Health. The psilocybin high-
dose (HD, 250 µg/kg), low-dose (LD, 125 µg/kg), and lactose placebo (PL) were administered in 
gelatine capsules of identical number and appearance. On three experimental days, separated 
from each other by at least two weeks, the subjects came to the lab at 9 am and confirmed they 
had not eaten breakfast or taken caffeine that morning. In a cross-over randomised design, all 
subjects received placebo and the two graded doses of psilocybin.
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3.3.3 Stimulus and procedure
The Kanizsa experiment started 120 min post-drug ingestion. During the experiment Kanizsa-
figures and control figures were presented at a distance of 1 meter from the participants while 
they remained fixated on a central fixation-cross. All stimuli consisted of three “pacmen”, each 
composed of a black circle with a sector of 60 degrees removed. The removed sectors were ei-
ther aligned such that the stimulus types induced the perception of an illusory triangle or they 
were rotated by 180 degrees so as to no longer induce the illusory triangle percept (‘Kanizsa’ and 
‘non-Kanizsa’ conditions respectively; see Figure 1). The stimuli subtended a visual angle of 3.7° 
and the support ratio, the ratio of the inducing length to the total length of one illusory contour 
of the triangle, was 1:2. In order to reduce habituation, the stimuli were presented in four differ-
ent orientations of equal number, rotated 0°, 90°, 180°, and 270°.
A total of 88 Kanizsa-figures and 88 non-Kanizsa-figures were presented with a stimulus onset 
asynchrony (SOA) of 3 seconds in a pseudorandomized order in two blocks consisting of 44 Kaniz-
sa-figures and 44 non-Kanizsa-figures each. Participants were required to respond, as quickly as 
possible, with a button press according to whether or not they saw an illusory triangle on each 
trial. The response finger was counterbalanced across the subjects to control for faster reaction 
times of index finger compared to middle finger of the dominant hand. Stimuli remained on the 
monitor for 300 msec after button-press or for a maximum of 2000 msec. 
3.3.4 Psychometry
The Altered States of Consciousness (5D-ASC) rating scale (34) was used to asses the subjective 
effects of placebo and psilocybin with a primary focus on visual alterations and hallucinations. 
The 5D-ASC is a visual-analogue scale consisting of 94 items that measure etiology independent 
alterations in consciousness, including changes in mood, perception, cognition and experience of 
self and of the environment. The five main factors are: (1) Oceanic Boundlessness, measuring 
derealization and depersonalization accompanied by changes in affect ranging from heightened 
mood to euphoria, and alterations in the sense of time. (2) Anxious Ego Dissolution measuring 
ego-disintegration associated with loss of self-control, thought disorder, arousal, and anxiety. (3) 
Visionary Restructuralization (VR) assessing visual illusions and (pseudo-) hallucinations, which 
includes the whole spectrum ranging from elementary to complex hallucinations. (4) Auditory 
Alterations (AA) comprising auditory illusions and (pseudo-) hallucinations. (5) Reduction of Vig-
ilance assessing changes in vigilance and alertness. The results of the 5D-ASC data are given as 
percentage scores of maximum absolute scale values.
Chapter 3 68
3.3.5 EEG recording
EEG recordings were made using BioSemi ActiveTwo electrode system with 64 scalp electrodes. 
Additional electrodes were attached on the outer canthus of each eye to record the horizontal 
electroocculogram (EOG) and infraorbitally and supraorbitally to the left eye to record the vertical 
EOG. Electrophysiological signals were band-pass filtered at 0.01–67 Hz and digitized at 256 Hz.
3.3.6 EEG analysis
EEG data were recalculated offline against average reference and band-pass filtered at 1–40 Hz. 
Correct response trials were segmented from -150 to +600 ms relative to stimulus presentation. 
To avoid eye movement and other artifacts in further analysis, epochs exceeding ±100 µV in any 
channel were excluded. The mean ± SD number of accepted epochs per condition was 85.0 ± 5.4 
for Kanizsa placebo, 85.0 ± 3.0 for non-Kanizsa placebo, 82.9 ± 4.6 for Kanizsa low-dose, 83.2 ± 
3.7 for non-Kanizsa low-dose, 78.8 ± 9.4 for Kanizsa high-dose, 79.4 ± 9.8 for non-Kanizsa high-
dose. These epochs were averaged time-locked to Kanizsa- and non-Kanizsa-figure presentation 
time to compute the VEP. The 600 ms poststimulus period of the VEP underwent three different 
analyses to reveal the VEP waveforms, the scalp topography and the source localization. This 
combination of analysis methods has been increasingly used during the last years, as it reduces 
experimenter bias associated with the selection of the appropriate time window for statistical 
analysis of the components (35).
Waveform analysis
To quantify waveform modulations, five symmetrical pairs of electrodes were selected over 
the maxima of the scalp topographies for the P1 and N170 components (PO7/PO8, PO3/PO4,   
O1/O2,P1/P2, P3/P4). The specific time windows used for calculation of the mean amplitude 
(versus the baseline) were determined by the topographic analysis described below. The mean 
amplitudes of each of these time windows were then subjected to separate repeated measures 
analysis of variance (ANOVA) with the within-subject factors dose (PL,LD,HD) electrode (PO7/PO8, 
PO3/PO4, O1/O2, P1/P2, P3/P4), hemiscalp (left, right) and stimulus (Kanizsa, non-Kanizsa).
Topographic analysis
First a spatial k-means cluster analysis identified the predominant topographies (also called 
 template map) appearing in the normalized group-averaged ERPs as a function of time and ex-
perimental condition (36). This analysis was constrained by the temporal criterion, that certain 
topographies must be observed for at least 5 consecutive data points (>20 ms at a 256 Hz sam-
pling rate). The optimal number of topographies that explained the whole dataset was deter-
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mined by a modified cross-validation criterion (36). In a second step we statistically verified that 
maps identified at the group-averaged level also appeared on the individual subject level. There-
fore, at each time point the topography of the individual subjects’ ERP was compared by means 
of strength-independent spatial correlation to all template maps and was labeled according 
to the one with which it best correlated (35,37). This revealed values of relative map presence 
(in milliseconds), which were then subjected to a repeated measures ANOVA using stimulus con-
dition, map and dose as within-subject factors. 
Source Localization
Standardized low-resolution electromagnetic tomography (sLORETA) was used to estimate the 
three dimensional intra-cerebral current density distributions underlying the ERPs within the 
time frames defined by topographic analysis. sLORETA offers a solution of the inverse problem 
by assuming that the smoothest of all possible activity is the most plausible one (38). The solu-
tion space of sLORETA (i.e. the lead field matrix) includes 6239 voxels and was computed with 
a three-shell spherical head model registered to the neuroanatomical atlas of Talairach and 
Tournoux (Brain Imaging Centre, Montreal Neurological Institute). 
Correlational analyses 
Correlational analyses were performed to determine whether psilocybin-induced changes in the 
current source density within the time frames defined by topographic analysis were related to 
visual or auditory  hallucinations. First, the differences of the current source density between 
psilocybin conditions (low- and high-dose) and placebo were calculated separately. In a second 
step these data were pooled and the product-moment correlations between these differences 
and the VR and AA scores, respectively, were calculated for each voxel. Significant correlations 
were identified using nonparametric permutation testing (39) that determined the critical prob-
ability threshold values for the observed r-values with correction for multiple testing. 
3.4 Results
3.4.1 Psychometrics
The subjective effects of psilocybin were assessed by the 5D-ASC rating scale. Repeated measures 
ANOVA revealed a significant main effect of dose (F(2,32)=36.596, p<0.00001, η2=0.70), factor 
(F(4,64)=12.924, p<0.00001, η2=0.45) and dose × factor interaction (F(8,128)=7.09, p<0.00001, 
η2=0.31) . Bonferroni-corrected post-hoc analysis on the VR factor, which was of primary interest in 
regard to the current study, indicated a significant increase between placebo and low-dose psilocybin 
Chapter 3 70
(p<0.00001) as well as placebo and high-dose psilocybin (p<0.00001) but not low-dose and high-
dose psilocybin (p=0.178). Bonferroni-corrected post-hoc analysis on the AA factor revealed a sig-
nificant increase between placebo and high-dose psilocybin (p<0.05) but not placebo and low-dose 
psilocybin (p=1.0). 
3.4.2 Behavioral data
Reaction time was dose-dependently increased by psilocybin (F (2,32)=18.841, p<0.00001, 
η2=0.54) and was generally faster for Kanizsa- compared to non-Kanizsa-figure (F (1,16)=36.037, 
p<0.0001, η2=0.69) (Table 1). While psilocybin administration did lead to a dose-dependent 
 increase in error rates (F (2,32)=3.3291, p<0.05, η2=0.17), the error rates remained very low in 
all conditions (0.88% for placebo, 1.18% for low-dose, 1.92% for high-dose). We are therefore 
confident that participants were able to do the task under all drug conditions. 
3.4.3 Electrophysiological data
Under all 3 drug conditions both stimuli elicited prominent VEP, including the P100 and N170 
component (Figure 1) with a maximum over lateral occipital scalp areas (Figure 3). The sub-
sequent topographic analysis detected nine different scalp topographies, which accounted 
for the 600 ms post-stimulus periods across all conditions with a global explained variance (GEV) 
of 96.74%. The first three time periods of stable scalp topographies were identical across condi-
tions lasting from 0–86 ms, 90–144 ms, 148–223 ms (Supplementary Figure S1). These time pe-
riods were used to define the time window for quantifying the P1 and N170 VEP in a more objec-
tive manner (Murray et al., 2008) and for the subsequent source localization and correlation 
analysis (Analysis referring to the P300 component can be found in supplementary material). 
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P1 
During the time-range of the P1 component (90–144 ms) a 3 × 2 × 5 × 2 repeated measures  ANOVA 
(using dose, hemiscalp, electrode, and stimulus as within factors) revealed only a main effect of 
electrode (F (4,64)=33.42, p<0.00001, η2=0.68) and a significant interaction of electrode and 
dose (F (8,128)=3.43, P<0.01, η2=0.18). Performing bonferroni-corrected post-hoc analysis of 
this interaction, the P1 amplitude was found to be significantly increased from placebo only at the 
O1/O2 electrodes by low dose (p<0.05) and high dose (p<0.0001) psilocybin. No effect of psilo-
cybin was observed at other electrodes, nor did any other interaction reach significance. This 
 result indicates that the effect of psilocybin on the P1 component is locally restricted to occipital 
electrode sites and is independent of hemiscalp and stimulus condition (Figure 2). Furthermore, 
neither the main effect for dose (F (2,32)=0.95, p=0.39, η2=0.06), stimulus (F (1,16)=0.77, 
p=0.39, η2=0.05) nor hemiscalp (F (1,16)=1.71, p=0.21, η2=0.10) reached significance.
To further elucidate topographic modulation of the P1 component, the spatial correlation pro-
cedure was used first to assess the number of time frames a given topography from the group-
averaged data was present in a given condition across subjects (see methods). These values were 
subjected to a repeated measures ANOVA (using dose, stimulus, and map as within factors), 
which provided no evidence of topographic specificity to one stimulus or dose condition (all 
P’s>0.15).
B)A)
placebo PO7/PO8 PO7/PO8 PO7/PO8
P1 N170
low-dose
P1 N170
high-dose
P1 N170
Kanizsa
non-Kanizsa
Figure 1
A) Example of Kanizsa-figure and non-Kanizsa-figure. 
B)  Group-averaged VEP waveforms in response to 
Kanizsa-figures (black traces) and non-Kanizsa-fig-
ures (red traces) for placebo, low-dose and high-
dose condition averaged from the left and right 
posterior electrode sites PO7/PO8, where P1 and 
N170 amplitude was most pronounced. Dashed 
lines indicate the time period of stable topographic 
configuration of the P1 and N170 component. 
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Source estimation from the 90–144 ms period yielded activity within LOC and V2 in both hemi-
spheres across all conditions. The psilocybin-induced increase in the P1 component over O1/O2 
electrode sites seen in the VEP waveform-analysis was localized most strongly in V2 and extend-
ed to LOC and V1 in the right hemisphere in the high-dose condition. The psilocybin induced 
 increase in the source-density did neither correlate with visual (all P’s>0.17) nor with auditory 
hallucinations (all P’s>0.98).
N170
To quantify the modulation of the N170 component, area measurements over the 148–223 ms 
period were subjected to a 3 × 2 × 5 × 2 repeated measures ANOVA (using dose, hemiscalp, 
 electrode, and stimulus as within factors). Psilocybin dose-dependently decreased the N170 
 amplitude (F (2,32)=17.170, p<0.00001, η2=0.52) and bonferroni-corrected post-hoc analysis 
P1
N170
PO7/PO8/PO3/PO4/
O1/O2/P1/P2 /P3/P4 O1/O2
PO7/PO8/PO3/PO4/
O1/O2/P1/P2 /P3/P4 O1/O2
Figure 2
The bar graphs display mean areas of the P1 (top) and 
N170 (bottom) components measured from 10 parie-
to-occipital electrodes sites (left) and from occipital 
electrode sites O1/O2 (right) symmetrically localized 
over both hemiscalps (see Methods and Materials for 
details). Mean areas are displayed for Kanizsa-figures 
(black) and non-Kanizsa-figures (red) for all dose con-
ditions (PL = placebo, LD = low-dose, HD = high-dose). 
Vertical bars denote standard deviations. The y axis 
presents amplitude in microvolts (µV). 
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revealed that the magnitude differences were significant between all dose conditions (Figure 2). 
The significant interaction between dose and hemiscalp (F (2,32)=5.30, p<0.05, η2=0.25) and 
the visual inspection of the VEP indicated a stronger psilocybin-induced decrease over the right 
compared to the left hemiscalp. In accordance with numerous previous studies (20–25) a sig-
nificant main effect of the stimulus condition was observed (F (1,16) = 35.863, p<0.0001, 
η2=0.70), with a greater magnitude in the Kanizsa- compared to the non-Kanizsa-condition. This 
magnitude difference between Kanizsa- and non-Kanizsa conditions dose-dependently decreased 
as revealed by the significant interaction between dose and condition (F (2,32)=3.4485, p<0.05, 
η2=0.18). 
The topographic pattern analysis of the collective data indicated that the effects of strength 
modulation in the electrical field were not associated with topographic modulations. This was 
subsequently confirmed by subjecting individual subject data to repeated measures ANOVA (all 
P’s>0.25). 
LORETA source localization over the N170 period (148 – 223 ms)
Kanizsa – HD
0.000 2.250 4.500 6.750 9.000
Kanizsa – LD
Kanizsa – PL
non-Kanizsa – HD
non-Kanizsa – LD
non-Kanizsa – PL
difference – HD
difference – LD
difference – PL
– 2.500 – 1.667 – 0.833 0.000 0.833 1.667 2.500
A) B)
Figure 3
A) Group-averaged LORETA source estimations for 
each stimulus (Kanizsa, non-Kanizsa) and dose (PL= 
placebo, LD=low-dose, HD=high-dose) conditions over 
the N170 period (148–223 ms). B) Group-averaged dif-
ferences of the source estimations between Kanizisa 
and non-Kanizsa condition. 
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The source estimation revealed activity within LOC and V2 in both hemispheres in all conditions 
(Figure 3). Current source density was stronger within right-lateralized LOC and V2 in the Kanizsa- 
compared to non-Kanizsa-condition. Psilocybin dose-dependently decreased the differential 
 activation of the two stimulus conditions and reduced the current source density within LOC, V2 
and fusiform gyrus in both stimulus conditions. The psilocybin-induced current source density 
reduction over right-lateralized LOC, V2 and posterior parietal areas correlated significantly with 
the increased intensity of visual hallucinations (Figure 4), while no correlation could be revealed 
with auditory hallucinations (all P’s>0.64). 
3.5 Discussion
The present investigation revealed three main  findings. First, the data indicate that the mixed 
5-HT2A/1A-receptor agonist psilocybin distinctively modulates the two early visual processing 
components. Specifically, while we found a strong dose-dependent decrease of the N170 
 component (148 – 223 ms post-stimulus) the earlier visual P1 compo nent (90 –144 ms post-
stimulus) was slightly increased over occipital electrode sites. Second, the reduction of 
the N170 component was stronger for the  Kanizsa-figure condition as compared to the non-
Kanizsa condition. Third, during this time range the decrease in activation over right-lateralized 
extrastriate and posterior parietal cortex correlated with the reported intensity of visual 
 hallucinations.
The time frame of the N170 component has been regarded as a critical period for object com-
pletion based on numerous findings of enhanced N170 amplitude and underlying LOC and V2 
activation evoked by Kanizsa- compared to control figures (20–25). The preferential reduction 
of the N170 amplitude in Kanizsa compared to non-Kanizsa condition by psilocybin indicates a 
central role of the 5-HT2A/1A receptors in object-completion. Since two sub-processes of object 
completion, i.e. boundary completion (22) and region-based segmentation (25), have been 
Figure 4
The voxel-wise correlation between visual hallucina-
tions and placebo – psilocybin current source density 
difference revealed that psilocybin-induced decrease 
in current source density in right extrastriate areas 
and posterior parietal areas over the N170 period 
(148–223 ms) positively correlated with the intensity 
of visual hallucinations (significant areas p<0.05 are 
shown in red). 194 voxels reached 0.05 significance 
criterion with a mean r value of 0.57. 
Correlation analysis over the N170 period (148 – 223 ms)
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shown to underlay the enhanced N170 amplitude in the Kanizsa-condition, it would be interest-
ing to further investigate which of these two sub-processes is modulated by signal transmission 
at 5-HT2A/1A receptors. 
The finding that psilocybin slightly enhanced P1 amplitude may reflect a generalized effect of 
5-HT2A/1A mediated increase in perceived brightness which is often reported after indolamine 
hallucinogen administration (40). This is supported by previous studies using comparable 
Kanizsa-figures showing the P1 component to be sensitive to stimulus brightness (41) as well as 
eccentricity (20) and symmetry (41).
Given that psilocybin strongly decreased the N170 amplitude in both the Kanizsa and the non-
Kanizsa conditions, we suggest that it modulates additional processes beyond proper object 
completion. Disruption of these processes might play a role in visual hallucinations, since their 
reported intensity was significantly correlated with the 3-dimensional current source density 
reduction over right-lateralized LOC, V2 and posterior parietal areas during the time-frame of the 
N170 component. This localization is in agreement with previous imaging studies reporting 
 decreased extrastriate activation in response to external visual stimuli in patients with visual 
 hallucinations compared to patients without hallucinations (42–44). Furthermore, we found 
 decreased activation specifically during the time-range of the N170 component. Decreased acti-
vation during this time range has been previously reported in studies investigating acoustic 
(45,46) and visual hallucinations (23). We therefore suggest that decreased stimulus-induced 
activation in modality-specific cortical areas during the time range of the N1/N170 component 
may be a characteristic of acoustic as well as visual hallucinations. This relationship between the 
increased intensity of visual hallucinations and the decreased stimulus-evoked activation of 
 extrastriate areas during the time-range of the N170 component could reflect a competition for 
neuronal resources in the processing of internally (hallucination) and externally (sensory-driven) 
generated information (46,47). A comparable mechanism has previously been suggested to be 
relevant in the formation of acoustic hallucinations (48). Increased extrastriate activation which 
could interfere with the processing of external stimuli, has been observed previously during 
 visual hallucinations in the absence of external stimulation in different psychiatric disorders 
(43,49–51) as well as after psilocybin administration (29). In line with this interpretation we 
 additionally found a correlation between reduced posterior parietal activation and hallucinatory 
severity. The posterior parietal cortex controls attention to visual stimuli by modulating visual 
cortex activity (52) during the time-range of the N170 component (53). The reduced posterior 
parietal activation might therefore reflect a psilocybin-induced failure to allocate attention and 
thus neuronal resources to external stimuli. 
Importantly, we identified reduced extrastriate visual cortex activation during the time range 
of the N170 as a potential key component of 5-HT2A/1A agonist-induced visual hallucinations. 
Such a mechanism could also underlie the visual disturbances and hallucinations reported in 
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Parkinson and schizophrenia patients, since increased 5-HT2A receptor densities have been 
found in these conditions and associated with visual hallucinations (6, 8, 9). In support of this 
notion, Parkinson’s patients with visual hallucinations showed more pronounced impairments 
in visual object recognition (54, 55) and more prominent reductions in extrastriate cortex 
 activation to visual stimuli than patients without hallucinations (44). Moreover, a reduction of 
the N170 component has also been reported in schizophrenia patients and associated with 
 visual hallucinations using Kanizsa-figures (23). These observations are in line with our finding 
of a correlation between reduced extrastriate activation during the time range of the N170 
component and the intensity of visual hallucinations. It is noteworthy, however, that two other 
previous studies using Kanizsa-figures in schizophrenia reported either no reduction (24) or 
only a reduction at a trend level (56). The apparent discrepancy between these results and our 
findings may be due to the fact that only about 30% of schizophrenia patients typically report 
visual hallucinations (57) and many of the patients tested were medicated with atypical antipsy-
chotics with 5-HT2A antagonistic activity. It might, therefore be possible that a disrupted 5-HT2A 
receptor system may be relevant only to a subgroup of schizophrenia patients. Given that we 
did not find a decrease of the P1 component after psilocybin administration and the robust 
 reduction of the P1 component reported in schizophrenia (23, 24, 56, 58) was not associated 
with psychotic symptoms (58) suggests that the reduction of the P1 component in schizophre-
nia is not related to serotonergic alterations and may rather represent an endophenotype of 
the schizophrenia spectrum (58, 59).
Since psilocybin is a mixed 5-HT2A/1A agonist (60) resulting in downstream effects on the 
dopamine systems (61), the exact pharmacological mechanisms of the observed psilocybin 
 effects require further investigation. However, converging lines of evidence indicate that psilocy-
bin’s psychotomimetic effects are mediated through the 5-HT2A receptor activation (10,62). For 
example, behavioral effects of psilocybin are lacking in 5-HT2A receptor knockout mice (63) and 
in humans nearly all psychotomimetic effects including visual distortions and hallucinations can 
be blocked by the 5-HT2A antagonist ketanserin (64,65), but not by blocking downstream dopa-
minergic effects with haloperidol (64). These findings, in combination with evidence regarding 
the importance of the 5-HT2A receptors in the pathophysiology of visual hallucinations (6–9), 
indicate that the reported effects of psilocybin are likely to be mediated by 5-HT2A receptor 
 activation. However, given that 5-HT1A receptors additionally influence the psychotomimetic 
 effects of indolamine hallucinogens (66) and 5-HT1A receptors are widespread in the visual 
 cortex (1,2), further studies are needed to exclude an additional contribution of 5-HT1A receptor 
on the spatiotemporal dynamics of visual object completion and hallucinations. 
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3.9 Supplemental Information
P300 Waveform analysis
For the P300 component, mean amplitude measurements (versus the baseline) were conducted 
at standard P300 electrode sites Pz, Cz, Fz over the time range of 281–600 ms corresponding to 
the last 4 topographic maps. These values were subjected to a 3 × 3 × 2 repeated measures 
 ANOVA using dose (placebo, low-dose, high-dose), electrode (Pz, Cz, Fz), and stimulus (Kanizsa, 
Non-Kanizsa) as within factors.
ANOVA analysis yielded a main effect of electrode (F (2,32)=61.80, p<0.00001, η2=0.79) with 
greatest magnitude over Pz followed by Cz and Fz electrode sites. Psilocybin dose-dependently 
decreased the P300 amplitude (F (2,32)=26.77, p<0.00001, η2=0.63) and Bonferronicorrected 
post-hoc analysis indicated a significant magnitude difference between all dose conditions (Fig-
ure S2).
P300 Topographic analysis 
The topographic pattern analysis of the group-averaged data indicated distinct durations of 
 stable topographic distribution between different dose and stimulus conditions (Figure S1). To 
statistically confirm this finding, the duration of each map observed in the individual subject 
data was subjected to a repeated measure ANOVA. The significant interaction between dose and 
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map (F (16,256)=5.25, p<0.00001, η2=0.25) indicated that the configurations of the electric 
field underlying the P300 component varies depending on the dose. Subsequent Bonferronicor-
rected post-hoc analysis revealed that map 6 starting 277 ms after stimulus presentation lasted 
significantly longer in the high-dose compared to placebo condition (p<0.001) while map 8 last-
ed longer in placebo compared to high-dose condition (p<0.0001) (Figure S1).
Kanizsa – HD
Map 6
Map 8
non-Kanizsa – HD
non-Kanizsa – LD
Kanizsa – LD
non-Kanizsa – PL
Map 1
1 2 3 4 6 7 8 9
1 2 3 4 6 7 8 9
1 2 3 5 6 7 8 9
1 2 3 5 6 7 8 9
1 2 3 5 6 7 8 9
1 2 3 5 6 7 8 9
Map 2 Map 3
Map 5
Map 4
Map 6 Map 7 Map 8 Map 9
Kanizsa – PL
A) Segments of stable configuration of the electrical field under the global field power curve from 
 0-600 ms post-stimulus presentation as a function of dose and stimulus condition. 
B)  Isocontour voltage maps corresponding to the segments of stable configuration of the electrical field. 
 All maps are shown with the nose towards the top of the page and left hemiscalp on the left side. 
C)  The bar graphs display the results of the individual subject fitting procedure for map 6 (top) and 
 map 8 (bottom) for Kanizsa figures (black) and non-Kanizsa figures (red) for all dose conditions (PL = placebo, 
 LD = low-dose, HD = high-dose). Vertical bars denote standard deviations. Psilocybin dose-dependant 
 increased the duration of map 6, while the duration of map 8 was dose-dependant decreased by psilocybin.  
Figure S1
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Figure S2
A) Group-averaged VEP waveforms in response to Kanizsa figures (black traces) and 
 non-Kanizsa figures (red traces) for placebo, low-dose and high-dose condition at Pz electrode site. 
B)  The bar graph displays the mean area of the P300 component for Kanizsa figures (black) and 
 non-Kanizsa figures (red) for all dose conditions (PL = placebo, LD = low-dose, HD = high-dose). 
 Areas were measured from Fz, Cz and Pz electrodes sides versus the baseline. Vertical bars denote 
 standard deviations.
placebo low-dose high-dose
A) B)
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4.1 Abstract
Visual illusion and hallucinations are a hallmark of serotonergic hallucinogen-induced states of 
consciousness. Although the serotonergic hallucinogen psilocybin displays high affinity for vari-
ous serotonin (5-HT) subreceptors, recent evidence converge on the idea that 5-HT2A receptor 
activation may lead to increased cortical excitability and altered visual evoked cortical responses 
that underlay psilocybin-induced visual hallucinations. Here we assessed in healthy human 
 subjects the effect of psilocybin (215 µg/kg vs. placebo) on the alpha oscillations that regulates 
cortical excitation and on the early visual-evoked potentials P1 and N170. To disentangle the 
specific contribution of 5-HT2A receptors, subjects were pretreated with the preferential 5-HT2A 
receptor antagonist ketanserin (50 mg vs. placebo). We found that psilocybin strongly decreased 
prestimulus parieto-occipital alpha power and blocked subsequent stimulus-induced alpha 
 desynchronization, two effects that were reversed by ketanserin. Furthermore, the medial P1 
visual-evoked potential was selectively increased by psilocybin and selectively decreased by ket-
anserin. Finally, psilocybin strongly decreased the N170 potential associated with the formation 
of subjective perceptual alterations, both of which were blocked by the 5-HT2A antagonist ket-
anserin. These findings suggest that 5-HT2A receptor activation mediates the psilocybin-induced 
subjective perceptual alteration and may induce a processing mode, in which stimulus-driven 
cortical excitation is overwhelmed by spontaneous neuronal excitation. The reduction the N170 
visual-evoked potential might be a possible key mechanism of 5-HT2A receptor–mediated sub-
jective perceptual alteration, which may be implicated not only in psilocybin-induced states but 
also in psychiatric disorders. 
4.2 Introduction
Recent evidence from molecular, pharmacological and neuroimaging studies suggests a crucial 
role for serotonin 2A (5-HT2A) receptors in visual processing and the pathogenesis of visual hal-
lucinations. Specifically, 5-HT2A receptors are highly expressed in the visual cortex (Gerstl et al., 
2008; Watakabe et al., 2009; Moreau et al., 2010) and alterations in the their cortical density in 
Parkinson’s disease (Ballanger et al., 2010; Huot et al., 2010) and schizophrenia (González-Maeso 
et al., 2008) are associated with the appearance of visual hallucinations. Furthermore, 5-HT2A 
receptors activation predominantly mediates the visual hallucinations induced by serotonergic 
hallucinogens such as psilocybin and LSD (Vollenweider et al., 1998; Nichols, 2004; Vollenweider 
and Kometer, 2010), whereas the 5-HT2A receptor inverse agonist pimavanserin is an effective 
treatment for visual hallucinations in Parkinson’s disease (Meltzer et al., 2010). Despite the in-
creasingly recognized significance of 5-HT2A receptors in visual perception, the effect of 5-HT2A 
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receptor activation by psilocybin on the neurophysiological mechanisms of visual processing and 
hallucinations remain unknown. Therefore, we assessed the modulation of the prestimulus state 
of the parieto-occipital network and the subsequent stimulus-induced activity by 5-HT2A recep-
tor activation and evaluated the relationship of this modulation to the formation of visual per-
ceptual alterations, including visual hallucinations. 
The activation of 5-HT2A receptors increases the excitability of the visual cortex in animals in 
the absence of externally presented visual stimuli (Moreau et al., 2010). Computational models 
suggest that an increase in the excitability state of the visual cortex may destabilize spontaneous 
network activity, which produces elementary visual hallucinations (Ermentrout and Cowan, 1979; 
Bressloff et al., 2002; Gutkin et al., 2003; Butler et al., 2012). Parieto-occipital alpha oscillations 
are crucial for the modulation of visual network excitability, which strongly influence visual per-
ception (Thut et al., 2006; Romei et al., 2008a; Jensen and Mazaheri, 2010; Klimesch, 2011; 
Mathewson et al., 2011) and visual-evoked potentials (Gruber et al., 2005; Klimesch, 2011; Raja-
govindan and Ding, 2011). Therefore, 5-HT2A receptor activation might modulate alpha power, 
which could lead to an altered excitability that promotes the formation of visual hallucinations. 
In addition, 5-HT2A receptors activation may modulate the visual cortex response to external 
stimuli that are indexed by visual-evoked potentials, because the bioactive metabolite of psilocy-
bin unselectively activates the 5-HT2A receptor (Blair et al., 2000; Nichols, 2004) and increases 
the early P1 visual-evoked potentials throughout medial occipital regions (Kometer et al., 2011). 
In addition, psilocybin decreases the N170 potential associated with the intensity of psilocybin-
induced visual hallucinations (Kometer et al., 2011). The 5-HT2A receptors likely mediate this 
psilocybin-induced decrease in the N170 potential because 5-HT2A receptor activation pre-
dominantly mediates psilocybin-induced visual hallucinations (Vollenweider et al., 1998; Vollen-
weider and Kometer, 2010). However, psilocybin also activates 5-HT1A, 2C receptors (Nichols, 
2004; Vollenweider and Kometer, 2010), and at least the 5-HT1A receptor is also expressed with 
a low density in the visual cortex (Dyck and Cynader, 1993; Gerstl et al., 2008; Watakabe et al., 
2009). Therefore the question about the specific effect of 5-HT2A receptor activation on visual-
evoked potentials and the P1 potential in particular, remains unknown. 
4.3 Methods 
4.3.1 Subjects
Seventeen right-handed subjects (11 males, 6 females, mean age of 26.0 ± 4.36 years) were 
 enrolled. All subjects were healthy on physical examination, which included detailed blood 
 analyses and electrocardiography. The Mini-International Neuropsychiatric Interview, MINI-SCID 
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(Sheehan et al., 1998), the DIA-X diagnostic expert system (Wittchen and Pfister, 1997), and the 
Hopkins Symptom Checklist SCL-90-R (Derogatis, 1994) were used to exclude subjects with pres-
ent or antecedent psychiatric disorders or a history of major psychiatric disorders in first-degree 
relatives. A urine drug screen and a self-report drug use questionnaire verified the absence of 
substance dependence.
Subjects received a written and oral description of the study procedures and the effects and 
possible risks of psilocybin administration. Subjects provided written informed consent prior to 
study participation. One of the 17 subjects was excluded due to dizziness after the combined 
administration of psilocybin and ketanserin. The data of another subject were excluded from 
analyses because the majority of the trials were contaminated by artifacts. A total of 15 subjects 
were included in the statistical analysis. 
4.3.2 Substance and Dosing
A double-blind, placebo-controlled, within-subject, randomized design was used. Subjects 
 received on four experimental days that were separated by at least two weeks four different 
drug combinations: placebo and ketanserin (50 mg) (pretreatment) followed by placebo and 
psilocybin (215 μg/kg) (treatment) after one hour. These specific doses were chosen, because 
they have been shown to induce and block the associated changes in conscious states (Carter 
et al., 2005). The Kanizsa experiment began 90 min after treatment during the plateau of 
the peak subjective psilocybin effects (Studerus et al., 2011). Self-report questionnaires were 
completed 360 min posttreatment to retrospectively rate the subjective experience following 
drug intake.
The use of psilocybin in humans was authorized by the Swiss Federal Office of Public Health, 
Department of Pharmacology and Narcotics (DPN), Bern, Switzerland. The study was approved 
by the ethics committee of the University Hospital of Psychiatry, Zurich.
4.3.3 Self-report questionnaires
The Five Dimensions of Altered States of Consciousness (5D-ASC) questionnaire (Dittrich) was 
used to quantify the subjective psychological effects of drug administration, with a primary focus 
on visual alterations and hallucinations. The 5D-ASC is a visual analogue scale of 94 items that 
measure etiology independent alterations in consciousness, including changes in mood, percep-
tion, cognition, and experience of the self and the environment. The Visionary Restructuraliza-
tion factor of the 5D-ASC, which measures visual illusions and elementary and complex halluci-
nations, was the primary interest of the current study. We also used the finer subdivision of the 
5D-APZ in 11 subscales for exploratory analysis (Studerus et al., 2010). 
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4.3.4 Stimulus and procedure
Subjects remained fixated on a central fixation cross during Kanizsa and control figure presen-
tations. All stimuli included three “pacman” figures, i. e., a black circle with a 60° section re-
moved. The removed sectors were either aligned to induce the perception of an illusory triangle 
(“Kanizsa” condition) or rotated 180°, which no longer induced the illusory triangle perception 
(“non-Kanizsa” condition). The visual angle of the stimuli was 5.4° instead of the 3.7° used in our 
previous Kanizsa study (Kometer et al., 2011), because increased eccentricity induces higher P1 
amplitudes (Murray et al., 2002; Busch et al., 2004). The stimuli were presented in four orienta-
tions of equal number, rotated 0°, 90°, 180°, and 270°, to reduce habituation. In total, 88 Kanizsa 
figures and 88 non-Kanizsa figures were presented in a randomized order with a 3 sec stimulus 
onset asynchrony. Participants responded with a button press as quickly as possible when they 
perceived an illusory triangle on each trial. Stimuli remained on the monitor for 300 msec after a 
button press or for a maximum of 2000 msec.
4.3.5 EEG recording
Continuous EEG was acquired from 64 Ag-AgCl electrodes using the BioSemi ActiveTow electrode 
system. Additional electrodes were attached to the outer canthus of each eye and infraorbitally 
and supraorbitally to the left eye to record the horizontal and vertical electroocculograms (EOGs), 
respectively. Electrophysiological signals were band-pass filtered online between 0.01 and 67 Hz 
and digitized with a sampling rate of 512 Hz.
4.3.6 EEG analysis
Preprocessing
The EEG data were recalculated offline against the common average reference, and bad channels 
(< 2%) were interpolated using spherical splines (Perrin et al., 1989). EEG data were epoched from 
800 ms before to 600 ms after stimulus onset. An automatic artifact rejection excluded epochs in 
which voltage values of the raw unfiltered data exceeded ± 120 µV in four or more electrodes to 
avoid eye movements, periods of high muscle activity and other noise transients. The remaining 
epochs were screened manually to reject epochs with residual eye movement artifacts. 
Time-frequency analysis
Signals x(t) from each trial were convolved with a family of Morlet wavelets, w(t, fo) = A exp(-t2 / 2 σt2) 
exp (2iπ fot), where fo is the central frequency, and i is the imaginary part, to calculate phase and 
power at 1-Hz frequency steps between 4 and 100 Hz. Wavelets were normalized using the factor 
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A(w) = (σt √���π)-1/2. The family ratio, m = fo / σf = 5, was used, where σf is the width of the Gaussian 
shape in the frequency domain. This ratio was used to optimize the trade-off between the 
temporal and frequency resolutions of the wavelet convolution. 
The power for each trial was computed as the sum of the squares of the real and the imaginary 
Morlet wavelet components, which was subsequently averaged over single trials separately for 
all conditions. These power values were baseline corrected by subtracting the mean power over 
the -200 to 0 ms prestimulus interval to quantify the stimulus-induced power. 
The extent of normalized phase variability across trials for each condition was quantified using 
the phase-locking value PLV (also called intertribal coherence (ITC) or phase-locking factor) at 
each time point, t, and frequency, fo. This procedure yields a PLV measure that ranges from 0 to 
1. A value of 0 indicates completely randomized phases across different trials at a specific time 
point, t, and 1 indicates a consistent phase across trials. 
Event-related potential (ERP) analysis
Individual ERPs were computed as the average across all trials per condition after the band-pass 
filtering of the preprocessed data (see above) at 0.5–40 Hz. The P1 and N170 amplitudes were 
quantified against the 200 ms baseline as the mean amplitude during a 40 ms time frame that 
was centered on the peak maximum time point, which resulted in a time frame from 80–120 ms 
for the P1 and 150–190 ms for the N170. 
Statistical analysis
Three parieto-occipital regions of interest (ROIs) were selected for the statistical analysis of ERPs, 
alpha power and phase, including the following electrodes: parietal left (P3, P5, P7, PO3, PO7), 
parietal medial (POz, Oz, O1, O2, Iz) and parietal right (P4, P6, P8, PO4, PO8). These ROIs have 
previously been used to quantify alpha power and phase values (Zanto et al., 2011) and covered 
the maximal P1 and N170 amplitudes in the current study. 
Only the time frame between -600 ms and 400 ms was considered in the analyses of power 
and phase values to ensure that edge effects did not contaminate the statistical analyses (Cohen 
et al., 2007). Prestimulus alpha (8–12 Hz) power was collapsed over the -600 to 0 ms time frame. 
Poststimulus alpha power was collapsed into two time frames (0–200 ms and 200–400 ms) 
 because visual inspection of our data indicated a stimulus-induced increase during the first 
time frame (0–200 ms) and a strong alpha desynchronization during the second time frame 
(200–400 ms) (Figure 3).
All dependent variables were subjected to repeated-measures ANOVA (specific factors are 
defined in the results section), and Greenhouse-Geisser correction was applied. Bonferroni-cor-
rected post-hoc comparisons were performed based on significant main effects or interactions. 
Pearson’s product moment correlations were conducted to assess several hypothesis-driven 
Chapter 4 90
 relationships between physiological parameters and self-reported visual perceptual alterations. 
First, we replicate (Kometer et al., 2011) and specify the relationship between the psilocybin-in-
duced decrease of the N170 potential and perceptual alterations. Second, we tested whether 
increased excitability that is indexed with decreased alpha-oscillations (Thut et al., 2006; Romei 
et al., 2008a; Jensen and Mazaheri, 2010; Klimesch, 2011; Mathewson et al., 2011) results in 
 elementary hallucinations (Ermentrout and Cowan, 1979; Bressloff et al., 2002; Gutkin et al., 
2003; Butler et al., 2012) by correlating alpha power with the elementary hallucination subscale 
of the 5D-APZ (Studerus et al., 2010). Finally, psilocybin-induced changes in prestimulus alpha 
power were correlated with the psilocybin-induced changes in the P1 potential, because the 
prestimulus alpha power has previously been closely associated with the P1 potential (Klimesch, 
2011; Rajagovindan and Ding, 2011).
4.4 Results
4.4.1 Behavioral data
Psychometrics
Repeated-measures ANOVA on the 3 primary dimensions of the 5D-ASC rating scale using 
 pretreatment, treatment and dimensions as within factors revealed a main effect of treatment 
(F (1,14)=75.85, p<0.00000050) and a treatmen × pretreatment interaction (F (1,14)=85.05, 
p<0.00000025). Post-hoc analyses of this interaction indicated that treatment with psilocybin 
increased 5D-ASC scores after placebo pretreatment (p<0.000000011), but not ketanserin 
 pretreatment (p=1). The triple interaction between pretreatment × treatment × factor (F (2,28)= 
30.62, p<0.000000090) demonstrated a similar relationship for the Visionary Restructuralization 
subdimension; the strong psilocybin-induced increase (p<0.000036) was absent  after ketanserin 
pretreatment (p=1). The scores of the recently formed 11 subscales (see  Methods) were submit-
ted to a separate repeated-measures ANOVA. The triple interaction  between treatment × pre-
treatment × factor (F (10,140)=9.44, p<0.00000000000070) indicated that psilocybin robustly 
induced several perceptual alterations after pla cebo pretreatment,  including complex hallu-
cinations (p<0.0000001), elementary hallucinations (p<0.0000001),  audio-visual synethesiae 
(p<0.000043) and changed meaning of percepts (p<0.0000001).  However, no subscales were 
 altered after ketanserin pretreatment (all p values=1).
Reaction times (RT) and Error rates
RT for correct responses were not significantly altered by psilocybin (F (1,14)=2.163, p=0.16) 
or ketanserin (F (1,14)=0.192, p=0.090). Error rates remained low in all drug conditions, and 
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neither treatment (F (1,14)=0.21, p=0.65) nor pretreatment (F (1,14)=3.73, p=0.074) generally 
modulated error rates. However, the interaction between treatment and stumulus (F (1,14)=5.124, 
p<0.041) indicated that psilocybin increased error rates for Kanizsa stimuli (p<0.039) but not the 
non-Kanizsa stumuli (p=1).
4.4.2 Event-related potential analyses
 
P1
A repeated-measures ANOVA on P1 amplitudes (using pretreatment, treatment, stimulus and 
ROI as within factors) revealed a significant interaction between treatment and ROI (F(2,28)=8.153, 
p<0.0017) and pretreatment and ROI (F(2,28)=19.879, p<0.0000043). Post-hoc analyses of 
these interactions indicated that psilocybin selectively increased the P1 amplitudes over the 
 medial (p<0.045) but not the lateral parieto-occipital ROIs. In contrast, the P1 amplitudes over 
the  medial parieto-occipital ROI was selectively decreased by ketanserin (p<0.000003) (Figure 1).
N170
A repeated-measures ANOVA on N170 amplitudes (using pretreatment, treatment, stimulus 
and ROI as within factors) revealed a significant main effect of treatment (F (1,14)=5.336, 
p<0.037), which replicated a previous study of psilocybin-induced decrease in the N170 am-
plitude (Kometer et al., 2011). In addition, the significant interaction between  treatment and 
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Figure 1: Effect of psilocybin and ketanserin on the 
group-averaged event-related potential waveforms 
for the three  parieto-occipital ROIs. Placebo+Placebo 
(black), Placebo+Psilocybin (red), Ketanserin+Placebo 
(blue), Ketanserin+Psilocybin (green). 
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 pretreatment (F (1,14)=7.548, p<0.016) and the subsequent post-hoc analyses indicated that 
psilocybin treatment decreased the N170 component compared to placebo only after placebo 
pretreatment (p<0.006) but not ketanserin pretreatment (p=1) (Figure 1). Correlational analysis 
revealed that this psilocybin-induced N170 decrease correlated with the psilo cybin-induced 
 increase in Visionary Restructuralization (r=0.7253, p<0.0023), and several  subscales (complex 
imagery r=0.6100, p<0.0158; elementary imagery r=0.4857, p<0.0665;  Audio-visual synesthe-
siae r=0.5378, p<0.0388) (Figure 2). 
A significant main effect of stimulus was revealed (F (1,14)=113.107, p<0.000000044) be-
cause the N170 amplitude was higher for the Kanizsa stimuli than for the non-Kanizsa stimuli. 
However, the interaction of stimulus and treatment did not reach significance (F (1,14)=1.86, 
p=0.19) in contrast to our previous study (Kometer et al., 2011). We suggest that  although the 
slightly higher stimulus size may also have contributed to the lack of effect in the current study, 
the more complex pharmacological statistical design, which added additional variance, was 
probably the primary contributor. To confirm this hypothesis, we calculated an  additional ANOVA 
that included only the placebo+placebo and the placebo+psilocybin conditions. This ANOVA 
yielded a significant interaction between treatment and stimulus (F (1,14)=4.96, p<0.043), indi-
cating a stronger psilocybin-induced decrease in the N170 potential in the Kanizsa (p<0.00000015) 
compared to that in the non-Kanizsa condition (p<0.000089). 
 
4.4.3 Time-frequency analyses
Prestimulus alpha power
The alpha power (8–12 Hz) during the prestimulus time frame (-600 to 0 ms) was subjected to 
repeated-measures ANOVA (using pretreatment, treatment, stimulus and ROI as within factors). 
A main effect of ROI (F (2,28)=4.130, p<0.027) indicated that the alpha power was most pro-
nounced over the right parieto-occipital region. Psilocybin strongly decreased the  prestimulus 
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Figure 2: Correlation analysis between the psilocybin-
induced reduction of the N170 and the psilocybin- 
induced self-reported perceptual visual alterations. 
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alpha power (F (1,14)=13.777, p<0.0024). This decrease depended on the pretreatment con-
dition (F (1,14)=5.953, p<0.029) because the psilocybin-induced decrease in the alpha power 
was significant after pretreatment with the placebo (p=0.00064) but not ketanserin (p=0.498) 
(Figure 3). Correlational analysis revealed that the psilocybin-induced decrease in alpha 
power correlated significantly with the psilocybin-induced increase in the medial P1 potential 
(r= -0.6409, p<0.011).
Poststimulus Alpha Power
Repeated ANOVA on the poststimulus alpha power (using the pretreatment, treatment, stimu-
lus, time and ROI as within factors) revealed a main effect of time (F (1,14)=32.804, p<0.000052), 
indicating a decrease in alpha power from baseline level (i.e. indicating stimulus-induced alpha 
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Figure 3: Effects of psilocybin and ketanserin on alpha 
power over the three parieto-occipital ROIs. Top: Time 
course for alpha power (8–12 Hz) as a function of 
Placebo+Placebo (black), Placebo+Psilocybin (red), 
Ketan serin+Placebo (blue), Ketanserin+Psilocybin 
(green). Bottom: Time course for the difference be-
tween Psilo-Pla for all frequences (4–52 Hz). 
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desynchronization), during the 200–400 ms time frame (Figure 3). The significant interaction 
between time × treatment (F (1,14)=16.579, p<0.0011) revealed that  psilocybin reduced alpha 
desynchronization compared to placebo particularly during the 200–400 ms time frame 
(p<0.0000003). The 3-way interaction between treatment × pretreatment × time (F (1,14)=7.237, 
p<0.018) further indicated that this psilocybin-induced reduction of alpha desynchronization 
during the 200–400 ms time frame was reversed by  ketanserin pretreatment, because alpha 
 desychnroisation was significantly higher in the ketanserin+psilocybin condition than the 
placebo+psilocybin condition (p<0.000057). 
Phase-locking Index (PLI)
Repeated-measures ANOVA (using the pretreatment, treatment, time, stimulus and ROI as 
within factors) on the PLI revealed a main effect of time (F (1, 14) = 30.739, p < 0.00008), indicat-
ing particularly high PLI values during the 0 –200 ms time frame. The significant inter action 
 between pretreatment and time (F (1, 14) = 37.599, p < 0.000027) indicated that ketanserin 
 pretreatment decreased PLI during the 0 –200 ms time frame (p < 0.000057) but not during 
the 200 – 400 ms time frame (p = 0.439). This decrease was most pronounced over the medial 
 parieto-occipital ROI (p < 0.00000000017) followed by the left (p < 0.00040) and right parieto-
occipital ROIs (p < 0.0025) (pretreatment  ×  time  ×  ROI: (F (2, 28) = 5.556, p < 0.0093) (Figure 4). 
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Figure 4: Effects of psilocybin and ketanserin on the 
Phase-locking-index for the three parieto-occipital 
ROIs. Placebo+Placebo (black), Placebo+Psilocybin 
(red), Ketanserin+Placebo (blue), Ketanserin+Psilo-
cybin (green). 
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4.5 Discussion
The current study revealed that psilocybin strongly decreased prestimulus alpha power, but it 
blocked the stimulus-induced reduction in alpha power (i.e., it blocked alpha desynchroniza-
tion). Moreover, psilocybin decreased the N170 visual-evoked potential. These psilocybin-in-
duced  effects on alpha oscillation and N170 visual-evoked potentials were normalized by the 
5-HT2A antagonist ketanserin, indicating that 5-HT2A receptor activation is crucial in mediating 
these phenomenons. 
Alpha oscillations (8–12 Hz) have been identified as a major neural mechanism that regulates by 
inhibition the excitability level of cortical sensory networks (Thut et al., 2006; Romei et al., 2008a; 
Jensen and Mazaheri, 2010; Klimesch, 2011; Mathewson et al., 2011). A high parieto-occipital 
alpha power level was observed under placebo conditions during the prestimulus time range, 
which suggests a high level of inhibition that reduces the excitability of the visual network in the 
absence of task-relevant visual input (Klimesch, 2011; Palva and Palva, 2011). This high level of 
prestimulus alpha power was strongly attenuated by psilocybin and reversed by ketanserin 
 pretreatment, suggesting that the activation of 5-HT2A receptors increases the excitability of 
the visual network in the absence the absence of externally presented stimuli. By contrast, the 
stimulus-induced decrease in alpha power (i.e., “alpha-desynchronization”) at 200–400 ms 
poststimulus was blocked by psilocybin and again reversed by ketanserin pretreatment. This 
finding suggests, that 5-HT2A receptor stimulation disrupts stimulus-driven excitability, which is 
indexed by the stimulus-induced alpha-desynchronization (Klimesch et al., 1994; Hanslmayr et 
al., 2009; Klimesch, 2011).
This opposite effect of 5-HT2A receptor activation on the excitability of the visual network 
during the presence or absence of externally presented stimuli might reflect a bias away from 
external stimulus-driven towards an internal-driven information processing, which may underlie 
the formation of visual hallucinations (Allen et al., 2008; Kometer et al., 2011; Butler et al., 2012). 
For instance, several computational models postulate that an increase in the excitability of the 
visual network in the absence of visual input destabilizes spontaneous neuronal activity, which 
results in the formation of elementary visual hallucinations (Ermentrout and Cowan, 1979; Bress-
loff et al., 2002; Gutkin et al., 2003; Butler et al., 2012) that resemble the visual hallucinations 
produced by classic hallucinogens (Klüver, 1966; Siegel et al., 1975). In addition, an increased 
stimulus-independent excitability that is associated with low alpha power has been implicated in 
TMS-induced phosphenes because the likelihood of experiencing these percepts is higher during 
low compared high alpha powers (Romei et al., 2008b). Psilocybin strongly increased the excita-
bility in the absence of externally presented stimuli by decreasing alpha power and robustly 
 induced elementary hallucinations in almost all of the subjects, which suggests that these alpha 
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effects may be implicated in the formation of visual hallucinations. However, the correlation 
between the psilocybin-induced decrease in alpha power and the subject-reported intensity of 
visual hallucinations did not reach statistical significance, indicating that the alpha power decre-
ase may not be sufficient to generate a subjectively experienced visual hallucination.
The strong effect of 5-HT2A receptor activation on alpha power is consistent with the known 
anatomical and functional properties of 5-HT2A receptors in the visual cortex of animals. The 
5-HT2A receptors in the visual cortex are primarily expressed in layers 4–6 (Watakabe et al., 
2009; Moreau et al., 2010), which are crucially implicated in the generation of alpha rhythms 
(Steriade et al., 1990; Silva et al., 1991; Jones et al., 2000; Pinto et al., 2003; Bollimunta et al., 
2008; Sun and Dan, 2009; Bollimunta et al., 2011; Buffalo et al., 2011). Furthermore, activation 
of 5-HT2A receptors in the visual cortex alters the excitatory-inhibitory balance towards excita-
tion of neurons in layer V (Moreau et al., 2010). Excitatory synaptic inputs in layer V modulate 
 alpha oscillations (Jones et al., 2000; Karameh et al., 2006; Sun and Dan, 2009), which suggests 
that 5-HT2A receptor-induced excitatory effects are closely associated with alpha oscillations. 
Finally, assuming that the presentation of external stimuli predominantly increases the firing rate 
of visual neurons from the prestimulus level (Quiroga et al., 2005; Montemurro et al., 2008), 
the opposite effect of 5-HT2A receptor stimulation during the present and absence of sensory 
stimuli in this study is consistent with the suppressive effect of 5-HT2A receptor activation on 
visual neurons with high firing rates, and the facilitatory effect on neurons with low firing rate 
(Watakabe et al., 2009).
Serotonin 2A receptors further strongly modulated the visual cortex response that is indexed by 
the visual-evoked P1 and N170 potentials. Specifically, psilocybin increased the medial P1 poten-
tial, and the preferential 5-HT2A antagonist ketanserin decreased the P1 potential over the same 
electrode sites. These results suggest an opposing influence of 5-HT2A agonism and antagonism 
on P1 potentials. Furthermore, these opposing effects seems to be either associated with alpha 
power or phase locking, which corresponds with the findings that the P1 potential is related to 
alpha oscillations (Gruber et al., 2005; Sauseng et al., 2005; Fellinger et al., 2011; Klimesch, 2011; 
Rajagovindan and Ding, 2011). Specifically, the individual decrease in prestimulus alpha power 
by psilocybin was significantly correlated with the psilocybin-induced increase in the P1  potential. 
Assuming that the initial visual gain is modulated by the prestimulus alpha power (Rajagovindan 
and Ding, 2011) and the psilocybin-induced increase in medial P1 potential reflects increased 
activity in early visual structures (Kometer et al., 2011), the psilocybin-induced increase in pre-
stimulus excitability may have amplified the initial visual gain in early visual areas. In contrast, 
the decrease in the medial P1 after the administration of the 5-HT2A antagonist ketanserin was 
associated with a concomitant decrease in alpha phases locking, which was most pronounced 
over the medial parieto-occipital ROI. This result supports the notion that PLI and the P1  potential 
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are closely associated (Gruber et al., 2005; Fellinger et al., 2011) and that the attenuation of P1 
potential may be driven by a 5-HT2A receptor antagonism-induced disruption of alpha phase 
resetting.
Furthermore, the N170 potential was decreased by psilocybin and associated with perceptual 
alterations, including visual hallucinations and audiovisual synethesia. Both the N170 potential 
and the perceptual alterations were blocked by ketanserin. This result not only supports that 
5-HT2A rather than 5-HT1A receptor stimulation is the key mechanism of psilocybin-induced 
 visual hallucinations (Vollenweider et al., 1998; Kometer et al., 2011) and audiovisual synesthe-
sia, but further suggests that the decrease in the N170 potential is a crucial mechanism that 
underlies these 5-HT2A receptor-mediated subjective visual perceptual alterations. This mecha-
nism might also be implicated in the pathophysiology of visual hallucinations in a subgroup of 
schizophrenic patients that experience visual hallucinations because this subgroup has increased 
cortical expression of 5-HT2A receptors (González-Maeso et al., 2008) and a more pronounced 
attenuation of the N170 potential to visual stimuli (Spencer et al., 2004).
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5.1 The effects of psilocybin on emotional and visual processing
5.1.1 Emotional processing
We found that psilocybin biases emotional processing towards positive relative to negative infor-
mation across different psychological domains. Specifically, psilocybin predominantly induced 
positive mood states, which is evident by the marked increase in the scores of the “positive 
 affect” subscale of the clinically relevant PANAS questionnaire. The strongly significant increase 
in the scores of the “blissful” subscale of the 5D-ASC questionnaire further indicate that these 
positive mood states are dominated by feelings of peace, love and happiness. In contrast, nega-
tive mood states were not provoked by psilocybin, as none of the scores of the “negative affect” 
subscale of the PANAS, “anxiety” subscale of the 5D-ASC or State-Anxiety of the State-Trait 
 Anxiety Inventory were significantly altered from those of the placebo. 
Similar to these alterations in the subjective state, a positive emotional bias was revealed in 
our study at the behavioural level by the psilocybin-induced bias towards the recognition of 
positive compared to negative emotional states of human eye regions, a processing mode that 
may cause increased trust in other people (Bedi et al., 2010). Furthermore, we found that psilo-
cybin enhance the response bias towards positive relative to negative emotional stimuli in emo-
tional goal-directed behaviour assessed by the emotional go/nogo task. This was evidenced by 
the psilocybin-induced increase in reaction times to negative and compared to positive stimuli, 
which is indicative of a relative positive emotional bias (Murphy et al., 1999; Feder et al., 2011). 
Furthermore, psilocybin augmented the sequential contextual influence of emotional stimuli in 
a manner that is consistent with a positive emotional bias. Specifically, psilocybin augmented the 
effect that sequential repetition of positive stimuli facilitates processing (Schulz et al., 2007; 
Thomas et al., 2009), which was indicated by a particularly strong decrease in the reaction times 
to repeated positive stimuli after psilocybin administration. This sequential facilitating effect was 
absent for repeated negative stimuli in all drug conditions. Repeated negative stimuli even 
 increased the reaction times after psilocybin administration, which is indicative of an increased 
inhibition of negative concepts within the attentional (Joormann, 2004) or memory systems 
(Sass et al., 2011). 
A possible psilocybin-induced positive bias in the attentional system is supported by the here 
revealed effect of psilocybin on event-related potentials in the emotional go/nogo task. Specifi-
cally, psilocybin strongly decreased the P300 component in all valence conditions, but most 
prominently for the negative and neutral stimuli. This valence-dependent P300 decrease was 
equally present in both the go and nogo condition, which suggests that this psilocybin-induced 
change in emotional processing is neither specific to response selection (go) nor inhibition 
(nogo), but rather, reflects a more general process underlying the P300 potential. For instance, 
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the P300 has previously been associated with the amount of attentional resource allocation 
 (Polich, 2007), and several behavioural studies have previously demonstrated that psilocybin 
 attenuates attentional performance (Gouzoulis-Mayfrank et al., 2002; Carter et al., 2005; 
 Vollenweider et al., 2007; Quednow et al., 2011). Therefore, the strong psilocybin-induced 
 decrease of the P300 that was revealed in all valence conditions may reflect an important 
 electrophysiological index of the previously reported psilocybin-induced attentional deficits. 
 Furthermore, the decrease was also valence-dependent, which suggests that psilocybin may 
 attenuate the allocation of attentional resources to neutral and negative stimuli more strongly 
than to positive stimuli and therefore, produce a relative positive attentional bias.
Taken together, our results from self-report, behavioural and neurophysiological measurements 
demonstrate for the first time that psilocybin shifts emotional processing towards positive and 
away from negative information, an effect that is consistent across different psychological do-
mains, including emotional face recognition, emotional goal-directed behaviour and mood states. 
5.1.2 Visual processing
The analysis of the spatiotemporal dynamic of visual modal object completion provides impor-
tant insights regarding the effect of psilocybin on the visual cortex response to external visual 
stimuli and the relationship of these effects to the formation of visual hallucinations. Specifically, 
we found that the early cortical response to visual stimuli, indexed by the P1 potential, was 
slightly increased by psilocybin over the medial occipital electrode sites, and the sLORETA analy-
sis localised this increase to the early visual areas. The psilocybin-induced increase in the P1 
amplitude may reflect an increase in perceived brightness, which has previously been shown to 
modulate the P1 potential response to Kanizsa figures (Proverbio and Zani, 2002) and is often 
reported after indolamine hallucinogen administration (Siegel and Jarvik, 1975).
In contrast to this initial increase in early visual cortex activity, we found that psilocybin dose-
dependently decreased the N170 potential. The N170 potential is critical for object completion 
because Kanizsa figures evoke a higher N170 amplitude and underlying LOC and V2 activation 
compared with control figures (Murray et al., 2002; Murray et al., 2004; Spencer et al., 2004; 
Foxe et al., 2005; Murray et al., 2006; Seghier and Vuilleumier, 2006; Yoshino et al., 2006; Knebel 
and Murray, 2012). Psilocybin produced a more pronounced reduction of the N170 amplitude 
and activation of the LOC in response to Kanizsa figures compared with the non-Kanizsa figures, 
which indicates that psilocybin disrupts the neuronal processes of modal object completion. 
 Because object completion is crucial for coherent visual perception (Lesher, 1995), and in par-
ticular, to delineate multiple objects from each other or their background (Stanley and Rubin, 
2003; Yoshino et al., 2006), the disruption likely contributes to psilocybin-induced altered visual 
perceptual experiences. 
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Direct support for the view that the N170 potential modulation is associated with subjective 
perceptual alterations derives from the finding that the reported intensity of visual hallucina-
tions and audiovisual synaesthesia correlated with decreases in the N170 amplitude in both the 
Kanizsa and non-Kanizsa conditions. Exploring the relationship between visual hallucinations and 
the N170 potential decrease in greater detail indicated that the psilocybin-induced reduction of 
the current source density in the right-lateralised LOC, V2 and posterior parietal areas correlated 
significantly with the intensity of visual hallucinations. This localisation is in line with the results 
of previous imaging studies reporting decreased extrastriate activation in response to external 
visual stimuli in patients with visual hallucinations compared with patients without hallucina-
tions (Howard et al., 1995; Ffytche et al., 1998). Furthermore, we found that the activation was 
selectively decreased during the time course of the N170 potential. Decreased activation during 
this time period has previously been reported in studies investigating acoustic (Tiihonen et al., 
1992; Hubl et al., 2007) and visual hallucinations (Spencer et al., 2004). Therefore, the decreased 
stimulus-induced activation in modality-specific cortical areas during the time course of the 
N1/N170 potential may be a characteristic of both acoustic and visual hallucinations. 
During the post-N170 period, psilocybin strongly and dose-dependently reduced the P300 
 potential in the modal object completion task, an effect that was also revealed in the emotional 
goal-directed behaviour task (see Chapter 5.1.1). The attenuation of the P300 potential in 
the modal object completion task may be fostered by a psilocybin-induced disruption of the 
shift from occipital to parietal processing because the microstate analyses revealed that the 
 occipital electrophysiological configuration appearing at the beginning of the P300 potential 
time period was prolonged by psilocybin, whereas the later parietal configuration was shortened 
by psilocybin. 
Psilocybin, however, not only modulated the visual cortex response to external visual stimuli, 
as indicated by the analysis of the spatiotemporal dynamic of visual modal object completion, 
but further strongly affected the pre- and poststimulus alpha oscillations. Specifically, psilocybin 
differentially influenced the alpha power during the pre- and poststimulus time-range. During 
the prestimulus time-range psilocybin strongly decreased the high level of parieto-occipital 
alpha power that was observed in the placebo condition. Parieto-occipital alpha power inhibits 
the excitability of the visual network (Foxe et al., 1998; Thut et al., 2006; Klimesch et al., 2007; 
Romei et al., 2008a; Romei et al., 2008b; Jensen and Mazaheri, 2010; Klimesch, 2011; Mathew-
son et al., 2011), and therefore, the psilocybin-induced decrease in the prestimulus alpha 
 power may  reflect a disinhibition that increases the excitability state of the visual cortex in 
the absence of direct stimulus-driven processing. In contrast to this prestimulus increase in excit-
ability, psilocybin blocked the stimulus-induced decrease in alpha power (i.e., blocked “alpha 
desynchronization”) 200–400 ms poststimulus, which indicates that psilocybin decreases the 
stimulus-driven excitation. 
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This opposite effect of psilocybin on the excitability during the presence and absence of direct 
stimulus-driven processing suggests that psilocybin induces a processing mode, in which sponta-
neously self-organised patterns of neuronal excitation overwhelm the visual stimulus-driven 
neuronal excitation. Thus psilocybin seems to disrupt the normal processing mode, in which 
spontaneously patterned neuronal activity is inhibited to keep the perceptual consequences 
subliminal (Ermentrout and Cowan, 1979; Bressloff et al., 2001, 2002; Billock and Tsou, 2007; 
Rule et al., 2011; Butler et al., 2012). According to computational models, an increase in spon-
taneous neuronal activity promotes the formation of elementary visual hallucinations (Ermen-
trout and Cowan, 1979; Bressloff et al., 2001, 2002; Billock and Tsou, 2007; Butler et al., 2012), 
which are phenomenologically similar to the elementary visual hallucinations that are produced 
by classical hallucinogens (Klüver, 1966; Siegel and Jarvik, 1975). Psilocybin induced elementary 
hallucinations and decreased inhibition by decreasing the alpha power in almost all of the 
 subjects, which suggests that these alpha effects may be implicated in the formation of visual 
hallucinations. However, the correlation between the psilocybin-induced decrease in alpha oscil-
lations and the subject-reported intensity of visual hallucinations did not reach statistical signifi-
cance, indicating that the alpha power decrease may not be sufficient to generate subjectively 
experienced visual hallucinations. 
Together these results show for the first time the various effects of psilocybin on the neuro-
physiological processes of visual perceptions in human subjects. These effects include a decrease 
of prestimulus parieto-occipital alpha activity that results in an increased prestimulus excitability 
state of the visual pathway. Although this psilocybin-induced increase in prestimulus excitability 
may contributed to augment the initial visual cortex response to visual stimuli that is indexed by 
the increased medial P1 potential (discussed in detail in Chapter 4), later stages in the processing 
of visual stimuli seems to be generally disrupted by psilocybin because psilocybin decreased the 
N170, the P300 potential and the stimulus-induced alpha-desynchronization.
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5.2  The role of serotonin subreceptors in emotional and visual 
processing
5.2.1 Emotional processing
Although the psilocybin-induced state is consistently characterised by a bias towards positive 
compared to negative emotional states across different psychological domains, we revealed that 
different serotonin subreceptors mediate the psilocybin-induced emotional effects. 
Activation of the 5-HT2A receptors is responsible for the psilocybin-induced positive mood 
states, indicated by the finding that the psilocybin-induced increase in the scores of the 
 positive mood subscales of the PANAS and the 5D-ASC questionnaires was blocked by the 
 preferential 5-HT2A antagonist ketanserin. These strong mood-enhancing effects of 5-HT2A 
receptor activation contrast with the usually absent acute mood effects of drugs that modu-
late the serotonergic tone such as acute tryptophan depletion (Hayward et al., 2005; Robinson 
and Sahakian, 2009; Roiser et al., 2009) or selective serotonin reuptake inhibitor (SSRI) admin-
istration (Harmer et al., 2003; Bhagwagar et al., 2004; Harmer et al., 2008). This apparent 
disparity suggests that 5-HT2A is much more closely linked to mood state than the seroto-
nergic tone. 
In addition, 5-HT2A receptors appear to be crucially implicated in the recognition of negative 
facial expressions because ketanserin blocked the psilocybin-induced attenuation in recognising 
negative emotional states from the eye region of human faces. This finding is in line with the 
central role of serotonin in emotional facial recognition, as previously established by pharma-
cological (Harmer et al., 2003; Bhagwagar et al., 2004; Hayward et al., 2005; Bedi et al., 2010; 
Victor et al., 2010) and genetic studies (Hariri and Holmes, 2006), but it extends this notion by 
showing that specific activation of 5-HT2A receptors likely biases facial recognition away from 
negative emotion. 
In contrast to the crucial contribution of 5-HT2A receptors to modulating mood states and emo-
tional face recognition, the psilocybin-induced effects on the emotional processing bias in the 
go/nogo task were not blocked by pretreatment with ketanserin. Thus, the psilocybin-induced 
emotional bias might be due to the stimulation of 5-HT1A or 5-HT2C receptors instead of 5-HT2A 
receptors. However, the strong valence-independent reduction of the P300 observed after psilo-
cybin administration was partially reversed by ketanserin, indicating an involvement of 5-HT2A 
receptors in the valence-independent attentional performance. 
These findings provide the first evidence for the effects of 5-HT2A receptor activation on 
 emotional processing in different psychological domains. In particular, a crucial role for 5-HT2A 
receptor activation in enhancing mood states and in disrupting the recognition of negative facial 
expressions was identified. These results demonstrate the feasibility of using psilocybin in 
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 combination with ketanserin to further elucidate the role of 5-HT2A receptor in emotional 
 processing. 
5.2.2 Visual processing
Serotonin 2A receptors strongly contribute to the effects of psilocybin on the P1 and N170 
 visual-evoked potentials. Specifically, the preferential 5-HT2A antagonist ketanserin blocked the 
psilocybin-induced decrease of the N170 potential and the associated psilocybin-induced visual 
hallucinations and audio-visual synaesthesia. These findings not only support the idea that 
5-HT2A rather than 5-HT1A receptor stimulation is the key mechanism for the generation of 
 visual hallucinations (Vollenweider et al., 1998) and audiovisual synaesthesia, but further sug-
gest that the decrease in the N170 potential is a crucial mechanism that underlies the 5-HT2A 
receptor-mediated subjective visual perceptual alterations. 
Furthermore, an opposing influence of 5-HT2A agonism and antagonism on the P1 potential is 
indicated by the finding that the preferential 5-HT2A antagonist ketanserin decreased the P1 
potential over the same medial electrode sites, where psilocybin increased the P1 potential. The 
P1 increase by psilocybin was linked to the modulations of the prestimulus alpha power (see 
above), whereas the decrease of the P1 potential by ketanserin was associated with a concomi-
tant decrease in alpha phase locking. The latter finding supports the notion that alpha phase 
locking and the P1 potential are closely associated (Gruber et al., 2005; Fellinger et al., 2011; 
Klimesch, 2011), and that the attenuation of the P1 potential may be driven by a 5-HT2A recep-
tor antagonism-induced disruption of alpha phase resetting.
In addition, a crucial contribution of 5-HT2A receptor activation to the mediation of the 
 psilocybin-induced effects on the alpha power was revealed in our study by the finding that the 
preferential 5-HT2A antagonist ketanserin blocked the pre- and poststimulus effects of psilocybin 
on the alpha power. This strong effect of 5-HT2A receptor activation on alpha power is consistent 
with the known anatomical and functional properties of 5-HT2A receptors in the visual cortex 
of animals. The 5-HT2A receptors in the visual cortex are primarily expressed in layers 4–6 
(Watakabe et al., 2009; Moreau et al., 2010), which are crucially implicated in the generation of 
alpha rhythms (Steriade et al., 1990; Lopes da Silva, 1991; Silva et al., 1991; Jones et al., 2000; 
Pinto et al., 2003; Bollimunta et al., 2008; Sun and Dan, 2009; Bollimunta et al., 2011; Buffalo 
et al., 2011). Furthermore, the activation of 5-HT2A receptors in the visual cortex alters the 
 excitatory-inhibitory balance in favour of excitation of pyramidal neurons in layer 5 (Moreau et 
al., 2010). Excitatory synaptic inputs in layer V modulate alpha oscillations (Jones et al., 2000; 
Karameh et al., 2006; Sun and Dan, 2009), which suggests that the 5-HT2A receptor-induced 
 excitatory effects are closely associated with alpha oscillations. Furthermore, assuming that the 
presentation of external stimuli predominantly increases the firing rate of visual neurons from 
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the prestimulus level (Quiroga et al., 2005; Montemurro et al., 2008), the opposite effects of 
5-HT2A receptor stimulation on the pre- and poststimulus alpha power are consistent with the 
suppressive effect of 5-HT2A receptor activation on visual neurons with high firing rates, and the 
facilitating effect on neurons with low firing rates (Watakabe et al., 2009).
Taken together, we revealed several 5-HT2A dependent neurophysiological mechanisms 
 underlying visual processing. Out of these mechanisms, the decrease of the N170 potential 
by 5-HT2A receptor activation was most closely associated with visual hallucinations, indicating 
that the decrease might a crucial mechanism of 5-HT2A receptor mediated visual hallucinations. 
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5.3 Implications for psychiatric disorders
5.3.1 Implications for mood disorders
Psilocybin produced in our emotional study behavioural and electrophysiological emotional 
 effects that were opposite to the dysfunctional emotional processing bias observed in de-
pressed subjects in emotional facial recognition (Bhagwagar et al., 2004; Hayward et al., 2005; 
Joormann and Gotlib, 2006; Victor et al., 2010), goal-directed behaviour (Murphy et al., 1999; 
Erickson et al., 2005; Krompinger and Simons, 2009) and mood states (Lovejoy and Steuerwald, 
1995; Peeters et al., 2003). In emotional facial recognition, psilocybin selectively disrupts the 
recognition of negative facial expressions, whereas depressed subjects have lower recognition 
rates for positive compared with negative expressions (Bhagwagar et al., 2004; Hayward et al., 
2005; Joormann and Gotlib, 2006; Victor et al., 2010). In the emotional go/nogo task psilocybin 
increased the reaction times and decreased the P300 amplitudes, particularly for negative and 
neutral stimuli, while depressed subjects were delayed in responding to positive cues (Murphy 
et al., 1999; Erickson et al., 2005) and displayed an increased P300 component for negative 
 stimuli (Krompinger and Simons, 2009). Finally, depressed subjects have decreased positive 
 affect scores in the PANAS (Lovejoy and Steuerwald, 1995; Peeters et al., 2003), and in contrast 
psilocybin selectively increases positive affect scores in the PANAS. 
Thus, this contrasting pattern suggests that psilocybin has the potential to acutely shift the 
negative emotional processing biases in depressive patients towards positive emotions. This shift 
supports the putative antidepressant potential of psilocybin (Vollenweider and Kometer, 2010; 
Grob et al., 2011) because a shift in the emotional processing bias is implicated in therapeutic 
effects of SSRIs (Harmer, 2008), and cognitive behavioural therapy (Disner et al., 2011). This acute 
psilocybin-induced shift may result in a sustained positive bias through psilocybin-induced 
 neuroplastic effects (Vollenweider and Kometer, 2010) or through psychological relearning pro-
cesses that are associated with a shift in the emotional processing bias (Harmer et al., 2009; 
Pringle et al., 2011; Sharp and Cowen, 2011).
Specifically, indolamine hallucinogens such as psilocybin induce several neuroplastic effects, 
including, for instance, a temporary downregulation of 5-HT2A receptor density (Buckholtz et al., 
1990), the induction of BDNF (Vaidya et al., 1997; Cavus and Duman, 2003) and an alteration of 
the spine morphology of prefrontal cortical neurons (Jones et al., 2009). Because the current 
study revealed that the acute shifts in mood state and emotional face recognition are mediated 
by 5-HT2A receptor activation, it is conceivable that these neuroplastic effects involve the modu-
lation of 5-HT2A receptor density or signalling. 
From a psychological perspective, an acute shift in the emotional processing bias could foster 
the relearning of new positive emotional associations brought about by the exposure to social 
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and emotional stimuli. Subsequently, this might lead to an improvement in depressive symptoms 
because new, positive emotional contingencies are experienced (Harmer et al., 2009; Pringle et 
al., 2011; Sharp and Cowen, 2011). Taken together, a possible mechanism underlying the anti-
depressant effect of psilocybin may be an acute psilocybin-induced shift in the emotional bias 
that leads in conjunction with neuroplastic effects and psychological relearning processes to an 
improvement in depressive symptoms.
Furthermore, the revealed contributions of the serotonin 2A receptor to the psilocybin-in-
duced positive processing bias have implications for the mechanisms underlying the patho-
physiology and serotonergic treatments of dysfunctional emotional biases. Specifically, agonistic 
action at the 5-HT2A receptors was identified in the current thesis as a mechanism for shifting 
emotional facial recognition and mood states towards positive emotions. A disruption in this 
mechanism may be implicated in the repeatedly observed dysfunctional emotional processing 
biases in facial recognition and mood state in depression because depressed subjects often have 
altered density of 5-HT2A receptors (Meyer et al., 1999; Meyer et al., 2001; Bhagwagar et al., 
2006; Shelton et al., 2009). Furthermore, this mechanism might even underlie the therapeutic 
action of SSRIs because chronic administration of SSRIs to depressed patients not only shifts 
negative mood states and negative bias in facial recognition (Burghardt et al., 2004; Victor et al., 
2010) but also seems to normalise the alterations in 5-HT2A receptor densities (Meyer et al., 
2001; Yamauchi et al., 2006).
5.3.2 Implications for schizophrenia and Parkinson’s disease
We identified several key neurophysiological mechanisms that underlie 5-HT2A agonist-induced 
alterations in visual processing. These mechanisms could also underlie the visual distur-
bances and hallucinations observed in Parkinson’s disease and schizophrenia patients because 
increased 5-HT2A receptor densities have been found in these psychiatric disorders and have 
been associated with visual hallucinations (González-Maeso et al., 2008; Ballanger et al., 2010; 
Huot et al., 2010). 
In particular, we identified reduced extrastriate visual cortex activation during the time course 
of the N170 potential as a potential key mechanism of 5-HT2A agonist-induced visual hallucina-
tions. This mechanism may also be implicated in the pathophysiology of visual hallucinations in 
Parkinson’s patients because patients with visual hallucinations showed stronger reductions 
in extrastriate cortex activation to visual stimuli (Meppelink et al., 2009) and more pronounced 
impairments in visual object recognition (Meppelink et al., 2008; Koerts et al., 2010) than 
 patients without hallucinations. Similarly, an attenuated N170 potential in response to Kanizsa- 
and non-Kanizsa figures has also been observed in schizophrenia patients, and it was found to 
be most prominent in patients with visual hallucinations (Spencer et al., 2004), supporting the 
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idea that a 5-HT2A receptor-mediated decrease in the N170 may also underlie visual hallucina-
tions in schizophrenia patients. However, it is noteworthy that two other previous studies using 
Kanizsa figures in schizophrenia patients reported either no reduction (Foxe et al., 2005) or only 
a trend towards a reduction (Spencer et al., 2003). A possible reason for the inconsistency in 
the findings regarding the N170 potential may be the fact that only approximately 30% of 
 schizophrenia patients typically report visual hallucinations (Bracha et al., 1989). This subgroup 
of patients with hallucinations has increased cortical expression of 5-HT2A receptors (González-
Maeso et al., 2008) and a more pronounced attenuation of the N170 potential (Spencer et al., 
2004). Therefore, it is conceivable that dysfunction of the 5-HT2A receptor and the associated 
decrease of the N170 potential may be a pathophysiological mechanism in a subgroup of schizo-
phrenic patients with visual hallucinations.
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5.4 Future research questions
5.4.1 Generalisation and specification of the psilocybin-induced emotional processing bias
The current thesis revealed a psilocybin-induced shift in the emotional processing bias, an effect 
that was consistent over different emotional domains. Therefore, the psilocybin-induced shift 
in emotional processing bias may be generalisable to other psychological dimensions such as 
the consolidation and retrieval of emotional memory, the formation of self-referential schemas, 
expectations and decision-making, which should be tested in further studies 
Moreover, the results of the emotional go/nogo task suggested that psilocybin induced a 
 positive attentional bias. However, whether an increase in the endogenous allocation of atten-
tional resources to positive stimuli or an increase in the stimulus-driven (external) attention to 
positive stimuli underlies this psilocybin-induced positive bias, remains to be determined. To 
elucidate this issue further, we began to assess in 15 healthy subjects the influence of psilocybin 
and ketanserin on the extend that visual processing is modulated by endogenous attention to 
external stimuli, by the salience of external stimuli or by the interaction between these variables. 
To simultaneously manipulate these factors, two vertical and two horizontal stimuli were pre-
sented together, which were all emotional, all neutral or a combination of both (manipulation of 
emotional salience). Additionally, the subjects were instructed to either look at the horizontal 
or vertical stimuli (manipulation of endogenous allocation of attentional resources). These two 
manipulations were independent, which allowed the experimental assessment of the interaction 
between emotional salience and endogenous attention. To quantify visual processing as a func-
tion of these manipulations, we used an experimental design called frequency tagging, which 
has previously been used to isolate the neuronal response to simultaneously presented visual 
stimuli (Morgan et al., 1996; Müller et al., 1998; Ding et al., 2006). Specifically, the simultane-
ously presented stimuli flicker at different frequencies. The SSVEPs are elicited by the flicker, and 
therefore, have exactly the same frequency as the presented stimulus. Accordingly, the process-
ing of the different stimuli can by assessed by a frequency analysis. A preliminary analysis of the 
results of this experiment in 8 subjects indicates that psilocybin generally increases the process-
ing of positive stimuli, but in particularly when endogenous attention is directed to the stimuli.
5.4.2 Alpha, excitability and visual percepts 
The effect of psilocybin on the relationships between visual percepts, excitability and alpha oscil-
lations can be explored further with a combination of the TMS and EEG methods. For instance, 
the threshold for TMS-induced phosphene, which is the intensity level at which phosphenes are 
perceived, is a reliable marker for the excitability of the visual cortex (Kammer et al., 2001; Gothe 
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et al., 2002). This threshold has been shown to be inversely related to the alpha power (Romei et 
al., 2008b; Romei et al., 2010) and to be reduced in conditions that have an increased prevalence 
for visual hallucinations, such as migraine (Gerwig et al., 2005), light deprivation (Boroojerdi et 
al., 2000), pregeniculate blindness (Gothe et al., 2002) or Lewy body dementia (Taylor et al., 
2011). Accordingly, assessing the influence of psilocybin on the threshold of TMS-induced phos-
phene and relating this threshold to the appearance of visual hallucinations and alpha power 
may be helpful for further elucidating the exact causal relationships between excitability, alpha 
power and the formation of visual hallucinations in hallucinogen-induced states. 
Furthermore, the 5-HT2A receptor-mediated decrease of the alpha power may not only lead 
to perceptual consequences of spontaneous, self-organised excitation patterns, as discussed 
above, but may also result in increased distractibility or working memory impairments. Specifi-
cally, the alpha power gates sensory input by inhibition (van Dijk et al., 2008; Rajagovindan 
and Ding, 2011), and therefore, is crucial for reducing interference with new sensory input 
during working memory maintenance (van Dijk et al., 2008; Haegens et al., 2012). Therefore, it is 
conceivable that the psilocybin-induced impairment in modulating alpha power revealed here 
contributes to the previously observed psilocybin-induced increase in distractibility (Carter et al., 
2005), working memory impairments (Wittmann et al., 2007) and attentional control deficits 
(Quednow et al., 2011), which should be tested in further experiments.
 
5.4.3 Alpha power and emotions
Several approaches from the visual and emotional experiments could be combined in further 
studies to reveal, for instance, the role of the alpha power in the anticipation of emotional 
 stimuli. The anticipation of a visual stimulus gradually decreases the parieto-occipital alpha 
 power immediately before stimulus presentation (Ergenoglu et al., 2004; Rohenkohl and 
 Nobre, 2011; Stokes et al., 2012), which is thought to reflect an adaptation of the excitability 
level for optimal stimulus processing. The anticipatory processes are modulated by the emo-
tional valence of a forthcoming stimulus (Bermpohl et al., 2006; Herwig et al., 2007). Therefore, 
it would be interesting to test whether the anticipation of a positive, negative or neutral visual 
stimulus may differentially modulate the alpha power immediately before stimulus presentation.
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